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ABSTRACT 
 
 
The contribution of chronic kidney disease measures to 
cause-specific mortality and morbidity 
 
Mok, Yejin 
Dept. of Public Health 
The Graduate School 
Yonsei University 
 
Chronic kidney disease (CKD) is increasing common public health problem worldwide. 
The association of CKD with cardiovascular disease (CVD) mortality is well known, 
however, the association with other causes mortality such as cancer is unclear. This study 
assessed the effects of CKD on the cause-specific mortality in a large cohort study. 
We studied 367,932 adults (20-93 years old) in the Metabolic Syndrome Mortality 
Study (health check-up database in Korea with baseline between 1994-2004) and 
233,219 adults (30-74 years old) in the Korean Heart Study (baseline between 1996-
2004). We assessed the associations of creatinine-based estimated glomerular filtration 
rate (eGFR) and dipstick proteinuria with mortality and morbidity due to CVD (1,608 
cases), cancer (4,035 cases), and non-CVD/cancer (3,152 cases) after adjusting for 
potential confounders. 
Lower eGFR (<60 ml/min/1.73m2 vs. ≥60 ml/min/1.73m2) was significantly associated 
with mortality due to CVD [hazard ratio (HR), 1.49 (95% CI, 1.24-1.78)] and non-
CVD/cancer [1.78 (1.54-2.05)]. Adjusted cancer mortality risk was the lowest at GFR 
45-59 and reached significance at eGFR <45 ml/min/1.73m2 [1.62 (1.10-2.39)] with 
eGFR 45-59 ml/min/1.73m2 as a reference. Proteinuria (dipstick ≥1+ vs. negative/trace) 
ix 
 
 
 
was consistently associated with mortality due to CVD [1.93 (1.66-2.25)], cancer [1.49 
(1.32-1.68)], and non-CVD/cancer [2.19 (1.96-2.45)]. Examination on causes of deaths 
suggested that low eGFR was significantly associated with higher mortality due to 
coronary diabetes, infectious disease, heart disease, oropharyngeal cancer, and renal 
failure, whereas proteinuria was related to mortality from coronary diabetes, infectious 
disease, heart disease, liver disease, myeloma, renal failure, stroke, and cancers of the 
stomach, liver, pancreas, and lung. When examining for morbidity, the study found a 
similar relationship with the results of mortality. Also, a rapid decline in eGFR inferred 
significantly greater risk for CVD mortality. 
Low eGFR was mainly associated with CVD and non-CVD/cancer mortality, whereas 
proteinuria was consistently related to mortality due to CVD, cancer, and non-
CVD/cancer. These findings suggest the need for multidisciplinary prevention and 
management strategies in individuals with CKD. 
 
keywords: eGFR, proteinuria, mortality, morbodity 
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I. INTRODUCTION 
 
Chronic kidney disease (CKD), which causes reduction in kidney function and/or 
kidney damage, is a common public health problem worldwide (Coresh et al. 2007; Jha et 
al. 2013; United States Renal Data System 2014). The prevalence of CKD is 10-15% in 
Asia, Europe, and the USA (Arora et al. 2013; Coresh et al. 2007; Health 2013; Imai et al. 
2009; Zhang et al. 2012). Individuals with CKD are at high risk of cardiovascular disease 
(CVD) and up to half of this population die due to CVD (Matsushita et al. 2010; Di 
Angelantonio et al. 2010; Hallan et al. 2007; Hemmelgarn et al. 2010; Nagata et al. 2013; 
Tonelli et al. 2006; Weiner et al. 2004; Wen et al. 2008). Indeed, numerous studies have 
reported the significant associations of low estimated glomerular filtration rate (eGFR) 
and high proteinuria with CVD mortality (Matsushita et al. 2010; Hallan et al. 2007; 
Nagata et al. 2013). 
Several studies also have report the association of CKD with all-cause mortality 
(Matsushita et al. 2010; Hemmelgarn et al. 2010; Tonelli et al. 2006; Weiner et al. 2004; 
Wen et al. 2008). This may merely reflect the fact that CVD is a leading cause of deaths 
in many place of the world (World Health Organization.Causes of death: Mortality and 
health status. WHO data and statistics). On the other hand, a few studies have reported 
the link of reduced kidney function to mortality due to cancer, the other worldwide 
leading cause of death (Fried et al. 2005; Iff et al. 2014; Weng et al. 2011). However, to 
our knowledge, only one study has simultaneously investigated CKD defined by both 
eGFR and proteinuria as recommended in clinical guidelines, in this context, and did not 
observe significant association between CKD and cancer mortality (Di Angelantonio et 
al. 2010). Thus, further studies are obviously needed, particularly for the potential 
relation between proteinuria and cancer mortality. 
Although CVD and cancer are clearly important as causes of death, other causes 
account for approximately 30-35% of deaths in developed countries (World Health 
Organization, 2014) and thus also warrant attention. A few studies have investigated an 
association of CKD with deaths due to non-CVD/cancer causes (Fried et al. 2005; Wang 
et al. 2011; Weng et al. 2011). In this context, infection mortality has been most 
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extensively examined but has demonstrated conflicting results across studies (Fried et al. 
2005; Wang et al. 2011; Weng et al. 2011). Moreover, the data on proteinuria are sparse 
(Wang et al. 2011) and causes of other infectious diseases are in need further 
investigations (Fried et al. 2005; Wang et al. 2011; Weng et al. 2011). 
However, these studies have predominantly considered the kidney function at one 
point but did not assess the association between changes in the kidney function and 
future risk. Understanding the dynamics of changes in kidney function using serious 
measurements may contribute to an additional prognostic beyond a single measurement. 
Although a limited number of studies has demonstrated an association between change in 
kidney function over time and adverse outcomes (Al-Aly et al. 2010; Matsushita et al. 
2009; Perkins et al. 2011; Rifkin et al. 2008). Also, it focused on cardiovascular disease 
or all-cause mortality.  
Since the prevention and management can be substantially different across diseases, 
quantifying the associations of CKD measures with cause-specific mortality in a single 
cohort is important from both clinical and public health perspectives. Therefore, the 
purpose of our study was to comprehensively assess whether creatinine-based eGFR and 
dipstick proteinuria are associated with mortality due to CVD, cancer, and other causes 
in a Korean cohort with data from more than 350,000 adults. The large sample size 
allowed us to also investigate finer causes of death (e.g., CVD subtypes, organ-specific 
cancer, and representative individual causes in non-CVD/cancer deaths). 
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II. OBJECTIVES 
 
The purpose of this study was to assess whether the association eGFR, dipstick 
proteinuria and cause-specific mortality in a prospective cohort investigation among 
large population in Korea. 
 
Specifically, 
1. To assess CKD attribute the cause-specific mortality 
2. To explore the association between CKD and cause-specific mortality  
3. To compare the change of eGFR adds additional information beyond that obtained 
by a single eGFR alone 
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III. MATERIALS AND METHODS 
 
A. Study population 
 
The Metabolic Syndrome Mortality Study (MSMS) is a retrospective cohort study 
based on private health examinations. We had collected the data of examinations 
conducted at 18 centers located in Seoul and six provinces in South Korea from 1994-
2004. Of these centers, 14 centers opted in to this cause-specific mortality study. The 
record linkage for mortality was based on an official personal identification number and 
resulted in 521,585 study members aged 20 years older at health assessment at baseline. 
Of these, we excluded participants with missing information on serum creatinine 
(n=37,196) and dipstick urinary test (n=116,457), leaving the final study population of 
367,932 participants.  
All Koreans are members of the National Health Insurance Service (NHIS). To ensure 
anonymity, all linkages were carried out by NHIS staff. The record linkage resulted in 
430,920 study members (266,782 men and 164,138 women) aged 30-74 years at health 
assessment at baseline between 1996 and 2004. We have labeled this study as the Korean 
Heart Study (KHS) (Jee et al. 2013). Of these we excluded participants with having 
cancer and cardiovascular at baseline (n=13,092), missing information on serum 
creatinine (n=126,994) and dipstick urinary test (n=57,615), leaving the final study 
population of 233,219 participants. 
The Institutional Review Board of Human Research of Yonsei University and all the 
individual health promotion centers participating in the MSMS and KHS approved the 
investigation. 
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Figure 1. Flow chart describing study population, Metabolic Syndrome Mortality Study 
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Figure 2. Flow chart describing study population, Korean Heart Study 
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B. Data collection 
 
Data were collected for demographic information, smoking status (never, past or 
current), and medical history of comorbidities such as CVD and cancer using a survey. 
Also, participants’ weight (with light clothes worn) and height were collected. Either 
registered nurses or nurse technicians measured blood pressure. Blood samples were 
obtained after 12hrs of fasting and serum was stored at -70°C. Total cholesterol, 
triglyceride, high-density lipoprotein cholesterol, fasting glucose, and liver function 
(aspartate aminotransferase, alanine aminotransferase) were done across at all centers 
using the Hitachi-7600 automatic analyzers (Hitachi Ltd, Tokyo, Japan). Viral hepatitis B 
and hepatitis C were measured in the serum with radioimmunoassay or reverse passive 
haemagglutination at participating laboratories. Each health center used internal and 
external quality control procedures as required by the Korean Association of Laboratory 
Quality Control. Each biomedical marker demonstrated high correlation across all 
centers (correlations coefficients ranging 0.96-0.99). Diabetes was defined as fasting 
glucose ≥126 mg/dl, use of glucose-lowering medication, or medical history of diabetes. 
 
C. Assessment of eGFR and dipstick proteinuria 
 
Serum creatinine was measured using he kinetic rate Jaffe method, and eGFR was 
estimated by the CKD-EPI equation (Levey et al. 2011), in which eGFR 
(mL/min/1.73m2)= 141 × min(Scr/k, 1)α × max(Scr/k,1)- 1.209 × 0.993age × 1.018 [if 
patient is female] × 1.159 [if patient is black], where age is in years, k is 0.7 for females 
and 0.9 for males, α is − 0.329 for females and − 0.411 for males, min indicates the 
minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1). Proteinuria was 
measured by dipstick test using an automated urine analyzer (URiSCAN Pro Ⅱ, YD 
diagnostics, South Korea), and was recorded as negative, trace, 1+, 2+, 3+, and 4+ across 
all centers except one health center. It was systematically recorded as negative and trace 
together as low proteinuria. 
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D. Change in eGFR 
 
An initial and final eGFR were obtained for a period of one year. This was used to 
estimate GFR using the CKD-EPI equation and dipstick proteinuria. Change in eGFR 
was defined as the change in eGFR category with confirmation based on percentage (%) 
change in eGFR [(last eGFR-first eGFR)/first eGFR X 100]. The groups for change in 
eGFR was defined as: ‘certain drop’ (drop in CKD category with ≥25% decrease in 
eGFR), ‘uncertain drop’ (drop in CKD category with <25% decrease in eGFR), ‘stable’ 
(no change or rise in CKD category). Similar to other studies, a 25% change in the eGFR 
was used to define certainty of change as this percentage reflect a true change in kidney 
function rather than variability in creatinine measurements related to the assay or intra-
individual serum creatinine variation across measurements (Turin et al. 2012).  
 
E. Follow-up for mortality and morbidity 
 
A computerized search for a death certificate was obtained using the aforementioned 
official identifier provided by the National Statistical Office in Korea through December 
31, 2011. The median follow-up was 9.8 years. Based on the International classification 
of diseases (ICD) code for primary cause of death and mortality was categorized into 
CVD (Disease of circulatory system: ICD-10 codes I00-I99 [Coronary Heart Disease: 
I20-I25, Stroke: I60-I69], Sudden death: R96), cancer (ICD-10 codes C00-C97), and non-
CVD/cancer (all causes other than CVD and cancer listed above). To assessment of finer 
cause of mortality, we also categorized into coronary heart disease (ICD-10 codes I20-
I25), stroke (I60-I69), cancer of oropharynx (C00-C14), oesophagus (C15), stomach 
(C16), colon (C18), rectum (C19-C20), liver (C22), gallbladder (C23), bile duct (C24), 
pancreas (C25), lung (C34), breast (C50), ovary (C56), urinary tract (C64-C68), brain 
(C71), unspecified sites (C76-C80), Non-Hodgkin’s lymphoma (C82-C85), myeloma 
(C90) and leukaemia (C91), infectious disease (certain infectious and parasitic 
diseases:A00-B99; nervous system: G00-G05, G08; circulatory system: I30, I32-I33, I38-
I41, I80-I88; respiratory system: J00-J06, J09-J18, J20-J22, J31-J32, J35, J37, J40-J42, 
J85-J86; digestive system: K05, K29, K65, K67, K73, K80-K81; skin and subcutaneous 
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tissue: L02-L05, L08; musculoskeletal system and connective tissue: M00-M01, M03), 
diabetes (E10-E14), Parkinson’s disease (G20-G21), chronic obstructive pulmonary 
disease (J42-J44), Interstitial pulmonary disease (J80-J84), liver disease (K70-K77), 
renal failure (N17-N19), general symptoms (R50-R69), unknown causes of mortality 
(R95, R97-R99), accidents (V00-X59) and suicide (X60-X84). 
This study conducted to confirm the findings of CVD, cancer, non-CVD/cancer 
mortality on morbidity data using data from the KHS. Outcomes were ascertained from 
diagnoses on hospital discharge summaries. For cancer and CVD incidence, one measure 
was constructed: at least one1 hospitalization for cancer or CVD. For non-CVD/cancer 
incidence, two measures were constructed: at least one hospitalization or three or more 
outpatient visits for non-CVD/cancer, then a summary measure was created for having at 
least one of these indicators.  
 
F. Statistical analysis 
 
i. Descriptive statistic 
 
Descriptive statistic are presented as mean and standard deviation (SD) for continuous 
variables or percentage for categorical variables across categories of eGFR (≥60 
[preserved eGFR], 45-59, 30-44 and <30 ml/min/1.73m2) and dipstick proteinuria 
(none/trace [reference], 1+, 2+ and ≥3+). An age-standardized cause-specific mortality 
rate was calculated for these categories for eGFR and proteinuria using the Korean 
Population (National Bureau of Statistics, 2010) 
 
ii. Association of eGFR and dipstick proteinuria with cause-specific mortality 
 
Cox proportional hazards models was used to quantify the association of eGFR and 
proteinuria with cause-specific mortality. For this main analysis, based on clinical 
guidelines and previous studies (Kidney Disease: Improving Global Outcomes 2013; 
Levey et al. 2011), we subdivided ≥90 and 60-89ml/min/1.73m2 into ≥105, 90-104, 75-89 
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and 60-74. Given that eGFR 75-89 ml/min/1.73m2 was the most prevalent category in 
those aged 50 years or older, a group with higher mortality risk than younger individuals, 
this category was selected as the reference for this analysis, as done in several previous 
studies (Di Angelantonio et al. 2010; Hallan et al. 2012). We used a restricted cubic 
spline function with six knots to plot this relationship, which allows for the assessment of 
non-linear effects of the exposure-outcome relationship. For dipstick proteinuria 
categories, none/trace was selected due to one center’s recording as negative and trace 
proteinuria for this category. However, using data from 13 centers, we also tested 
dipstick negative as a reference. Three models were constructed to evaluate the impact of 
potential confounders. Model 1 incorporated only age and gender. Model 2 further 
adjusted for the following conventional predictors: smoking status, body mass index, 
total cholesterol, systolic blood pressure, medication of hypertension, diabetes, and 
history of CVD and cancer, and each of CKD measures, as appropriate (dipstick 
proteinuria was accounted for in the analyses for eGFR and vice versa). To assess the 
robustness of our findings, we repeated our analysis in several subgroups by age (< and 
≥60 years), gender, and history of CVD and cancer at baseline. For finer causes of 
mortality, causes for more than 50 deaths were analyzed. To obtain reliable estimate, we 
modeled the kidney measures as dichotomous variables (eGFR < vs. ≥60 ml/min/1.73m2 
and dipstick proteinuria ≥1+ vs. none/trace).  
  
iii. Competing risk model 
 
Since competing events can impede the occurrence of the event of interest, competing-
risk regression was also considered to evaluate for a possible association between kidney 
measures and cause-specific mortality. Competing-risks regression is an alternative to 
Cox regression for survival data in the presence of competing risks. Based on the method 
of Fine and Gray (1999) (Fine et al, 1999), competing-risks regression posit a model for 
the sub-hazard function of a failure event of primary interest. 
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iv. Imputation 
 
The multiple imputations (van Buuren S et al, 1999) were implemented to impute 
missing values. The method based on conditional specification (FCS) was used, also 
known as “chained equations”. The observed values from the one variable were regressed 
on the other variables in the imputation model. Missing values in X1 are replaced by 
simulated draws from the corresponding posterior predictive distribution of X1. Then, the 
next variable with missing values, X2 say, is regressed on all other variables X1, X3, …, 
Xk, restricted to individuals with the observed X2, and using the imputed values of X1. 
Again, missing values in X2 are replaced by draws from the posterior predictive 
distribution of X2. The process is repeated for all other variables with missing values in 
turn: this is called a cycle (White IR et al, 2011). Theses regression models were 
operated under the same assumptions that one would make when performing linear 
(continuous) or logistic (binary) regression models outside of the context of imputing 
missing data. The missing values were replaced with predictions (imputations) from the 
regression model. We implemented multiple imputation (van Buuren S et al, 1999) to 
impute smoking status (200,887 participant with missing values), diabetes (20 
participants), systolic blood pressure (362 participants), and total cholesterol (17 
participants) using age, gender, history of cancer and CVD, body mass index, use of anti-
hypertensive drugs, eGFR, dipstick proteinuria, death due to CVD, cancer, or other 
causes, and follow-up time and performed 20 cycles.  
 
All analyses were performed using STATA statistical software version 12. All 
statistical tests were two-sided and statistical significance was determined as p<0.05. 
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IV.  RESULTS 
 
A. General characteristics of study population 
 
  The mean age of the study participants was 41.7 (SD, 10.9) years and 41.5% were 
women. Current smokers were substantially more common in men (54.4%) than in 
women (5.8%). The average eGFR was 94.2 (SD, 14.4) ml/min/1.73m2. Among the 
participants, 1.0% had eGFR below 60 ml/min/1.73m2 and 3.7% had dipstick proteinuria 
≥1+. The participants with lower eGFR (<60 ml/min/1.73m2) or higher dipstick 
proteinuria (≥1+) were more likely to be older, men and have diabetes, hypertension, and 
hypercholesterolemia compared with the participants with higher eGFR (≥60 
ml/min/1.73m2) and lower proteinuria (negative or trace), respectively (Table 1).  
  Table 2 shows the general characteristics of the study population by cause-specific 
mortality. Those who died from CVD, cancer and non-CVD/cancer were more likely to 
be old, men and had higher current smokers status, diabetes and hypertension compared 
with those who are living. The mean of eGFR by cause-specific mortality was 85.9, 82.3, 
86.1 and 94.4 ml/min/1.73m2 in cancer, CVD, non-CVD/cancer and alive, respectively. 
The proportion of dipstick proteinuria (≥1+) was 7.68, 13.25, 12.75 and 3.50 % in cancer, 
CVD, non-CVD/cancer and alive, respectively.  
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Table 1. Baseline characteristics by eGFR and dipstick in Korean Heart Study, N=367,932 
 eGFR, ml/min/1.73m2  Dipstick proteinuria 
 ≥90 60-89 45-59 <45  None/trace 1+ 2+ ≥3+ 
 N=227,370 N=136,920 N=3,136 N=506  N=354,433 N=10,090 N=2,545 N=864 
Age, years 38.2(9.3) 46.9(10.8) 61.2(9.9) 58.1(13.4)  41.6 (10.9) 42.7 (11.8) 44.2 (12.5) 47.1 (12.8) 
Female 44.51 36.33 53.09 46.05  41.80 34.07 36.27 34.95 
Smoking status          
 Ex-smoker 5.34 8.81 14.51 12.85  14.76 14.54 16.54 22.15 
 Current smoker 14.45 17.00 12.34 15.22  33.39 43.72 39.72 36.97 
Cardiovascular disease 0.35 0.79 3.22 3.56  0.51 1.14 1.57 1.50 
Cancer 0.19 0.26 0.48 0.59  0.21 0.37 0.24 0.35 
Diabetes 3.6 5.72 12.21 21.34  4.04 14.13 20.31 26.62 
Diabetes medication 0.57 0.96 3.19 7.51  0.66 2.59 3.50 8.33 
Fasting glucose, mg/dl 90.2(20.1) 94.3(21.8) 101.5(31.3) 103.6(35.5)  91.3 (19.6) 103.5 (38.5) 110.3 (46.3) 117.3 (54.4) 
Hypertension medication  1.56 3.96 15.05 26.28  2.42 6.40 9.19 14.81 
Hypertension 18.85 29.08 54.37 69.57  22.44 35.62 46.40 57.64 
SBP, mmHg 116.9(16.0) 122.1(18.1) 134.4(22.2) 142.0(25.6)  118.8 (16.9) 124.2 (20.4) 129.0 (23.2) 137.2 (27.0) 
DBP, mmHg 73.9(11.3) 76.5(12.0) 78.4(13.4) 82.4(15.5)  74.8 (11.5) 78.3 (13.3) 80.7 (14.6) 82.0 (15.2) 
Hypercholesterolemia 5.32 10.27 20.5 23.32  7.08 11.87 15.60 27.89 
Total-C, mmol/l 4.7(0.9) 5.0(0.9) 5.4(1.0) 5.3(1.4)  4.8 (0.8) 5.0 (1.0) 5.2 (1.1) 5.6 (1.3) 
HDL-C, mmol/l 1.3(0.3) 1.3(0.3) 1.3(0.3) 1.2(0.3)  1.3 (0.3) 1.3 (0.3) 1.3 (0.3) 1.2 (0.3) 
Triglyceride, mmol/l 1.5(1.1) 1.7(1.1) 1.9(1.2) 2.2(1.5)  1.6 (1.1) 1.8 (1.4) 2.0 (1.7) 2.3 (1.9) 
LDL-C, mmol/l 2.8(0.8) 3.0(0.8) 3.3(1.0) 3.2(1.2)  2.9 (0.8) 2.9 (0.9) 3.1 (1.0) 3.4 (1.2) 
Height, cm 165.3(8.3) 164.9(8.6) 160.1(8.6) 160.9(9.1)  165.1 (8.5) 165.8 (8.1) 164.9 (8.3) 164.4 (8.4) 
Weight, kg 63.0(11.5) 65.3(10.8) 63.6(10.4) 62.1(10.5)  63.8 (11.2) 65.4 (12.1) 65.8 (12.9) 65.4 (12.4) 
Body mass index, kg/m2 23.0(3.2) 23.9(3.0) 24.7(3.1) 23.9(3.3)  23.3 (3.1) 23.7 (3.5) 24.1 (3.8) 24.1 (3.7) 
Obesity 2.12 2.65 4.91 4.55  2.26 4.05 5.89 6.25 
Serum creatinine, mg/dl 0.8(0.1) 1.0(0.1) 1.2(0.2) 2.5(2.2)  0.9 (0.2) 1.0 (0.3) 1.0 (0.5) 1.3 (1.4) 
eGFR, ml/min/1.73m2 103.2(8.9) 80.3(7.1) 55.7(3.5) 32.6(11.5)  94.4 (14.2) 91.3 (16.5) 86.5 (20.6) 77.4 (26.5) 
SBP: systolic blood pressure; DBP: diastolic blood pressure; Total-C: Total cholesterol; HDL-C: HDL-cholesterol; LDL-cholesterol: LDL--cholesterol 
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Table 2. Baseline characteristics by cause-specific mortality 
 Cause-specific death 
 Cancer CVD Non-CVD/cancer Alive 
 N=4,035 N=1,608 N=3,152 N=359,137 
Age, years 55.5 (11.1) 57.8 (12.2) 54.6 (13.5) 41.3 (10.7) 
Female 26.62 30.04 28.55 41.87 
Smoking status     
 Ex-smoker 12.34 12.56 12.21 6.58 
 Current smoker 30.29 29.1 28.24 15.04 
Cardiovascular disease 1.16 3.67 1.4 0.51 
Cancer 0.97 0.50 0.22 0.21 
Diabetes 12.04 16.29 18.27 4.23 
Diabetes medication 2.50 2.80 3.68 0.69 
Fasting glucose, mg/dl 100.7 (30.2) 106.1 (40.2) 108.1 (44.8) 91.6 (20.3) 
Hypertension medication  5.48 11.26 6.63 2.50 
Hypertension 39.33 57.03 43.50 22.52 
SBP, mmHg 127.7 (20.9) 138.2(24.0) 128.9 (22.2) 118.8 (16.9) 
DBP, mmHg 76.7 (13.0) 80.3(14.3) 77.9 (13.4) 74.9 (11.6) 
Hypercholesterolemia 10.16 18.28 12.47 7.19 
Total C, mmol/l 4.9 (1.0) 5.2(1.1) 5.0 (1.1) 4.8 (0.9) 
HDL-C, mmol/l 1.3 (0.3) 1.2(0.3) 1.3 (0.3) 1.3 (0.3) 
Triglyceride, mmol/l 1.7 (1.2) 1.9(1.4) 1.9 (1.6) 1.6 (1.1) 
LDL-C, mmol/l 2.9 (0.9) 3.1(1.0) 2.9 (1.0) 2.9 (0.8) 
Height, cm 164.1 (8.0) 162.3(9.0) 163.2 (8.5) 165.1 (8.5) 
Weight, kg 63.4 (10.2) 63.5(11.1) 61.6 (10.9) 63.9 (11.3) 
Body mass index, kg/m2 23.5 (3.2) 24.0(3.3) 23.1 (3.3) 23.4 (3.1) 
Obesity 2.35 3.73 1.94 2.34 
Serum creatinine, mg/dl 0.9 (0.3) 1.0(0.4) 1.0 (0.6) 0.9 (0.2) 
eGFR, ml/min/1.73m2 85.9 (14.8) 82.3(17.0) 86.1 (18.2) 94.4 (14.3) 
Proteinuria (>=1+) 7.68 13.25 12.75 3.50 
SBP: systolic blood pressure; DBP: diastolic blood pressure; Total-C: Total cholesterol; HDL-C: 
HDL-cholesterol; LDL-cholesterol: LDL--cholesterol 
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B. Age-standardized mortality rate (per 1000 person-years) by eGFR and 
dipstick proteinuria 
 
During the median follow-up of 9.8 years, 8796 participants died (1,608 from CVD, 
4,035 from cancer, and 3,152 from non-CVD/cancer). Age-standardized mortality rate 
due to CVD, cancer, and non-CVD/cancer largely increased as eGFR decreased (Figure 
3). Regarding the proportion of each mortality cause, non-CVD/cancer was the most 
common cause of death only among those with eGFR above 90 ml/min/1.73m2 (42.0%), 
but death due to cancer were most common in eGFR 60-89 ml/min/1.73m2. Regardless of 
eGFR categories, CVD accounted least as a cause of mortality (18.9%-30.2%). Similarly, 
age-standardized mortality rate for CVD, cancer, and non-CVD/cancer tended to increase 
along with proteinuria. In terms of respective proportion, again, non-CVD/cancer were 
most common among those with positive proteinuria (dipstick ≥1+) (42.2%-54.0%), but 
cancer was the most common cause of death among those with none/trace dipstick 
proteinuria (41.7%). 
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Figure 3. Age-standardized mortality rate (per 100 person-years) by eGFR and dipstick 
proteinuria categories 
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C. Cause-specific mortality by eGFR 
 
Crude hazard ratios (HRs) for mortality due to CVD, cancer and non-CVD/cancer 
were significantly increased as eGFR levels decreased, with eGFR of 75-89 
ml/min/1.73m2 as a reference (Table 3). After adjusting for the potential confounders, 
eGFR categories below 60 ml/min/1.73m2 were significantly associated with higher 
mortality due to CVD and non-CVD/cancer, with higher HR for non-CVD/cancer 
mortality at a given eGFR category than for CVD mortality [e.g., HR 5.39 (95%CI 3.78-
7.70) for non-CVD/cancer mortality and 2.64 (1.42-4.89) in eGFR <30]. Risk of cancer 
mortality was lowest at eGFR 45-59 after the adjustment for potential confounders and 
reached at eGFR <45 ml/min/1.73m2 [1.62 (1.10-2.39)] with eGFR 45-59 as a reference. 
High eGFR was associated with lower risk of CVD, cancer, and non-CVD/cancer 
compared to the reference group in the crude model but showed higher risk once age and 
gender were taken into account. When we tested dichotomous eGFR, 
eGFR<60ml/min/1.73m2 was significantly associated with mortality due to CVD [1.49 
(1.24-1.78)] and non-CVD/cancer [1.78 (1.54-2.05)] compared to eGFR ≥60 
ml/min/1.73m2 in Model3. 
HRs for mortality due to CVD, cancer and non-CVD/cancer were significantly 
increased as eGFR decline before imputing to missing variable. Compared to imputed 
model, HRs for mortality due to CVD, cancer and non-CVD/cancer were similar, but 
slightly lower risk gradient for imputed model over non-imputed model. 
To consider failure events of primary interest, we used a competing-risks model. HRs 
for mortality due to CVD, cancer and non-CVD/cancer were significantly increased as 
eGFR decline (Table A1). Compared to not competing-risks model, HRs for mortality 
due to CVD, cancer and non-CVD/cancer were similar, but slightly at lower risk gradient 
for competing-risks model for CVD and cancer mortality, while higher risk gradient for 
competing-risks model for non-CVD/cancer mortality in lowest eGFR category 
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Table 3. Hazard ratios (95%CI) for cause-specific mortality by eGFR 
 eGFR, ml/min/1.73m2 
 ≥105 90-104 75-89 60-74 45-59 <45 
 N=87,468 N=139,902 N=105,839 N=31,081 N=3,136 N=338 
Cancer mortality       
 Cases 339 1,287 1,507 741 128 33 
 Crude 0.27 (0.24-0.30) 0.65 (0.60-0.70) 1.0 1.66 (1.52-1.81) 2.94 (2.45-3.52) 5.19 (3.67-7.32) 
 Model 1 1.28 (1.12-1.45) 1.09 (1.01-1.18) 1.0 0.91 (0.83-1.00) 0.75 (0.63-0.91) 1.46 (1.03-2.07) 
Model 2* 1.19 (1.02-1.40) 1.02 (10.93-1.11) 1.0 0.94 (0.84-1.05) 0.82 (0.66-1.02) 1.37 (0.92-2.04) 
 Model 2 (impute) 1.16 (1.02-1.32) 1.04 (0.97-1.13) 1.0 0.95 (0.87-1.04) 0.78 (0.65-0.94) 1.26 (0.88-1.80) 
CVD mortality       
 Cases 103 447 570 335 118 35 
 Crude 0.22 (0.18-0.27) 0.59 (0.53-0.67) 1.0 1.98 (1.73-2.27) 7.17 (5.88-8.74) 14.57 (10.35-20.49) 
 Model 1 1.19 (0.95-1.49) 1.05 (0.93-1.20) 1.0 1.03 (0.90-1.18) 1.62 (1.32-2.00) 3.59 (2.53-5.07) 
Model 2* 1.18 (0.89-1.57) 1.08 (092-1.25) 1.0 0.93 (0.79-1.10) 1.29 (1.00-1.66) 2.21 (1.48-3.30) 
 Model 2 (impute) 1.17 (0.93-1.46) 1.03 (0.91-1.17) 1.0 0.99 (0.86-1.13) 1.34 (1.90-1.66) 2.09 (1.45-3.01) 
Non-CVD/cancer mortality       
 Case 396 1,019 992 512 153 80 
 Crude 0.47 (0.42-0.53) 0.78 (0.71-0.85) 1.0 1.74 (1.56-1.93) 5.32 (4.49-6.31) 19.09 (15.20-23.97) 
 Model 1 2.01 (1.77-2.29) 1.26 (1.15-1.38) 1.0 0.99 (0.89-1.10) 1.48 (1.24-1.76) 5.86 (4.64-7.39) 
Model 2* 1.74 (1.48-2.06) 1.18 (1.06-1.32) 1.0 0.98 (0.86-1.12) 1.37 (1.10-1.69) 3.28 (2.45-4.38) 
 Model 2 (impute) 1.73 (1.51-1.91) 1.19 (1.09-1.30) 1.0 1.02 (0.92-1.14) 1.41 (1.18-1.68) 3.35 (2.61-4.31) 
All-cause mortality       
 Case 838 2,753 3,069 1,588 399 148 
 Crude 0.32 (0.30-0.35) 0.68 (0.64-0.71) 1.0 1.74 (1.64-1.85) 4.50 (4.05-4.90) 11.42 (9.67-13.47) 
 Model 1 1.53 (1.40-1.66) 1.14 (1.08-1.20) 1.0 0.96 (0.90-1.02) 1.16 (1.04-1.29) 3.24 (2.74-3.83) 
Model 2* 1.39 (1.25-1.54) 1.08 (1.01-1.15) 1.0 0.95 (0.88-1.03) 1.12 (0.98-1.27) 2.27 (1.86-2.77) 
 Model 2 (impute) 1.37 (1.26-1.49) 1.90 (1.03-1.15) 1.0 0.98 (0.92-1.04) 1.11 (1.00-1.24) 2.20 (1.84-2.63) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, current smoker, systolic blood pressure, anti-hypertensive, 
body mass index and dipstick proteinuria 
* used to analyze 166,867 population 
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Figure 4. Adjusted hazard ratio of cause-specific mortality by eGFR  
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D. Cause-specific mortality by dipstick proteinuria 
 
In contrast to eGFR, high proteinuria was consistently associated with all of CVD, 
cancer and non-CVD/cancer mortality outcomes, with robust dose-response relationship 
(Table 4). HR for non-CVD/cancer mortality was higher at any given proteinuria 
category followed by CVD and cancer mortality. For all mortality outcomes including 
cancer, risk was significantly increased even at 1+ proteinuria group [e.g., HR 1.45 (95% 
CI 1.26-1.66) for cancer]. With available data separating dipstick negative and trace, 
dipstick trace was significantly associated with increased risk of mortality due to CVD 
and non-CVD/cancer (Table 5). The association with cancer mortality was borderline 
significant [1.13 (0.99-1.29), p=0.075]. When we tested dichotomous dipstick proteinuria, 
positive proteinruia was significantly associated with mortality due to CVD [1.93 (1.66-
2.25)], cancer [1.49 (1.32-1.68)] and non-CVD/cancer [2.19 (1.96-2.45)] compared to 
none/trace. 
HRs for mortality due to CVD, cancer and non-CVD/cancer were significantly 
increased as high proteinuria before imputing to missing variable. Compared to imputed 
model, HRs for mortality due to CVD, cancer and non-CVD/cancer were similar, but 
slightly higher risk gradient for imputed model over non-imputed model. 
A competing-risks model was used to consider a failure event of primary interest. HRs 
for mortality due to CVD, cancer and non-CVD/cancer were significantly increased as 
eGFR decline (Table A2). Compared to not competing-risks model, HRs for mortality 
due to CVD, cancer and non-CVD/cancer were similar, but slightly at lower risk gradient 
for competing-risks model for CVD, cancer and non-CVD/cancer mortality. 
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Table 4. Hazard ratios (95%CI) for cause-specific mortality by dipstick proteinuria  
 Dipstick proteinuria 
 None/trace 1+ 2+ ≥3+ 
 N=354,433 N=10,090 N=2,545 N=864 
Cancer mortality     
 Case 3,725 219 59 32 
 Crude 1.0 1.85 (1.61-2.12) 2.18 (1.69-2.82) 3.22 (2.28-4.57) 
 Model 1 1.0 1.49 (1.30-1.70) 1.47 (1.14-1.91) 1.86 (1.31-2.63) 
Model 2* 1.0 1.32 (1.13-1.56) 1.55 (1.15-2.10) 1.82 (1.20-2.75) 
 Model 2 (impute) 1.0 1.45 (1.26-1.66) 1.47 (1.13-1.91) 1.87 (1.30-2.68) 
CVD mortality     
 Case 1,395 135 42 36 
 Crude 1.0 3.07 (2.58-3.66) 4.16 (3.06-5.65) 9.76 (7.01-13.59) 
 Model 1 1.0 2.40 (2.01-2.87) 2.67 (1.97-3.64) 5.33 (3.82-7.42) 
Model 2* 1.0 1.94 (1.58-2.39) 1.84 (1.28-2.65) 2.45 (1.62-3.70) 
 Model 2 (impute) 1.0 1.86 (1.55-2.24) 1.69 (1.23-2.32) 2.43 (1.68-3.51) 
Non-CVD/cancer 
mortality 
    
 Case 2,750 225 103 74 
 Crude 1.0 2.56 (2.23-2.93) 5.15 (4.23-6.27) 10.03 (7.96-12.64) 
 Model 1 1.0 2.13 (1.86-2.44) 3.65 (3.00-4.44) 6.12 (4.85-7.71) 
Model 2* 1.0 1.81 (1.55-2.13) 2.66 (2.07-3.41) 2.81 (2.03-3.89) 
 Model 2 (impute) 1.0 1.77 (1.54-2.03) 2.67 (2.17-3.28) 3.28 (2.52-4.28) 
All-cause mortality     
 Case 7,870 579 204 142 
 Crude 1.0 2.31 (2.13-2.58) 3.57 (3.11-4.10) 6.77 (5.73-7.99) 
 Model 1 1.0 1.88 (1.72-2.04) 2.43 (2.12-2.79) 3.94 (3.33-4.65) 
Model 2* 1.0 1.62 (1.47-1.79) 2.03 (1.71-2.40) 2.43 (1.96-3.01) 
 Model 2 (impute) 1.0 1.65 (1.51-1.80) 1.97 (1.71-2.28) 2.65 (2.20-3.18) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, 
current smoker, systolic blood pressure, anti-hypertensive, body mass index and eGFR 
* used to analyze 166,867 population 
22 
 
 
 
Table 5. Hazard ratios (95%CI) for cause-specific mortality by dipstick proteinuria in Korean Heart Study (excluding hospital #7), N=178,603 
 Dipstick proteinuria 
 none trace + ++ ≥+++ 
 N=154,739 N=14,272 N=7,320 N=1,598 N=674 
Cancer mortality      
 Crude 1.0 1.46 (1.28-1.68) 1.61 (1.47-1.77) 1.98 (1.60-2.45) 3.31 (2.51-4.36) 
 Model 1 1.0 1.16 (1.02-1.32) 1.44 (1.24-1.67) 1.52 (1.14-2.03) 1.92 (1.33-2.76) 
 Model 2 (impute) 1.0 1.13 (0.99-1.29) 1.40 (1.20-1.63) 1.53 (1.14-2.05) 1.89 (1.28-2.77) 
CVD mortality      
 Crude 1.0 1.87 (1.55-2.26) 3.19 (2.68-3.82) 4.33 (3.18-5.89) 10.17 (7.30-14.17) 
 Model 1 1.0 1.57 (1.29-1.90) 2.35 (1.93-2.86) 2.81 (1.98-3.98) 5.59 (3.92-7.95) 
 Model 2 (impute) 1.0 1.39 (1.15-1.69) 1.88 (1.53-2.30) 1.82 (1.27-2.60) 2.61 (1.75-3.88) 
Non-CVD/cancer mortality      
 Crude 1.0 1.85 (1.62-2.12) 2.67 (2.33-3.06) 5.36 (4.40-6.53) 10.47 (8.30-13.19) 
 Model 1 1.0 1.58 (1.37-1.81) 2.17 (1.87-2.52) 3.68 (2.94-4.62) 5.65 (4.35-7.32) 
 Model 2 (impute) 1.0 1.47 (1.28-1.69) 1.84 (1.58-2.14) 2.87 (2.27-3.62) 3.06 (2.27-4.13) 
All-cause mortality      
 Crude 1.0 1.30 (1.19-1.42) 2.08 (1.90-2.28) 3.20 (2.73-3.75) 5.61 (4.68-6.72) 
 Model 1 1.0 1.37 (1.26-1.49) 1.85 (1.69-2.03) 2.48 (2.12-2.91) 3.83 (3.20-4.59) 
 Model 2 (impute) 1.0 1.29 (1.19-1.41) 1.65 (1.50-1.81) 2.08 (1.76-2.44) 2.57 (2.10-3.14) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, current smoker, systolic blood pressure, anti-hypertensive, 
body mass index and eGFR
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E. Stratification by gender and age 
 
Table 6 shows the HRs for cause-specific mortality by eGFR and gender. Adjusted 
HRs for mortality due to CVD and non-CVD/cancer were significantly increased as 
eGFR levels decreased both of men and women. Also, High eGFR was associated with 
higher risk of non-CVD/cancer mortality compared to the reference group. However, 
HRs for mortality due to cancer was not significantly increased as eGFR levels decreased 
in both genders.  
High proteinuria was consistently associated with all of CVD and non-CVD/cancer 
mortality outcomes in both genders, with robust dose-response relationship (Table 7). In 
women, risk of CVD mortality was associated with only ≥3+ proteinuria [HR 3.80 
(95%CI 1.94-7.43)]. For cancer mortality, its association was significant in men, but not 
in women. 
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Table 6. Hazard ratios (95%CI) for cause-specific mortality by eGFR and gender 
 eGFR, ml/min/1.73m2 
 ≥105 90-104 75-89 60-74 45-59 <45 
Men (N=215,103) N=41,958 N=84,219 N=68,605 N=18,577 N=1,471 N=273 
Cancer mortality       
 Model 1 1.30 (1.11-1.52) 1.09 (1.00-1.20) 1.0 0.86 (0.77-0.95) 0.63 (0.50-0.79) 1.49 (1.00-2.23) 
 Model 2 1.15 (0.98-1.34) 1.03 (0.94-1.12) 1.0 0.91 (0.82-1.02) 0.66 (0.52-0.83) 1.27 (0.84-1.92) 
CVD mortality       
 Model 1 1.18 (0.91-1.54) 1.03 (0.88-1.19) 1.0 1.04 (0.88-1.23) 1.70 (1.31-2.21) 3.69 (2.34-5.82) 
 Model 2 1.12 (0.86-1.45) 1.01 (0.87-1.18) 1.0 1.01 (0.85-1.19) 1.36 (1.04-1.78) 2.08 (1.29-3.38) 
Non-CVD/cancer mortality       
 Model 1 2.13 (1.82-2.48) 1.32 (1.19-1.47) 1.0 0.98 (0.87-1.12) 1.47 (1.18-1.82) 5.74 (4.30-7.67) 
 Model 2 1.77 (1.52-2.07) 1.22 (1.10-1.36) 1.0 1.04 (0.92-1.19) 1.44 (1.16-1.79) 3.29 (2.42-4.49) 
All-cause mortality       
 Model 1 1.56 (1.41-1.73) 1.15 (1.08-1.23) 1.0 0.93 (0.87-1.00) 1.06 (0.93-1.22) 3.12 (2.53-3.83) 
 Model 2 1.36 (1.23-1.51) 1.09 (1.02-1.16) 1.0 0.97 (0.90-1.05) 1.04 (0.91-1.19) 2.12 (1.71-2.64) 
Women (N=152,829) N=45,510 N=55,683 N=37,234 N=12,504 N=1,665 N=233 
Cancer mortality       
 Model 1 1.09 (0.86-1.37) 1.09 (0.93-1.27) 1.0 1.06 (0.89-1.27) 1.13 (0.83-1.55) 1.44 (0.71-2.92) 
 Model 2 1.07 (0.85-1.35) 1.09 (0.93-1.27) 1.0 1.07 (0.90-1.27) 1.13 (0.82-1.54) 1.28 (0.62-2.64) 
CVD mortality       
 Model 1 1.37 (0.88-2.14) 1.13 (0.89-1.44) 1.0 1.02 (0.80-1.30) 1.46 (1.04-2.05) 3.03 (1.76-5.20) 
 Model 2 1.38 (0.88-2.17) 1.10 (0.86-1.40) 1.0 0.95 (0.75-1.22) 1.28 (0.91-1.81) 1.19 (0.67-2.11) 
Non-CVD/cancer mortality       
 Model 1 1.69 (1.33-2.15) 1.10 (0.93-1.31) 1.0 0.98 (0.80-1.20) 1.48 (1.09-2.01) 6.12 (4.14-9.06) 
 Model 2 1.58 (1.25-2.03) 1.09 (0.91-1.29) 1.0 0.97 (0.79-1.18) 1.32 (0.96-1.80) 3.21 (2.09-4.93) 
All-cause mortality       
 Model 1 1.39 (1.19-1.62) 1.10 (0.99-1.22) 1.0 1.03 (0.92-1.15) 1.37 (1.14-1.65) 3.58 (2.69-4.76) 
 Model 2 1.33 (1.14-1.55) 1.09 (0.98-1.21) 1.0 1.01 (0.90-1.14) 1.27 (1.06-1.53) 2.33 (1.72-3.16) 
Model 1: adjusted for age  
Model 2: adjusted for age, total cholesterol, diabetes, cardiovascular disease, cancer, current smoker, systolic blood pressure, anti-hypertensive, body 
mass index and dipstick proteinuria 
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Table 7. Hazard ratios (95%CI) for cause-specific mortality by dipstick and gender 
 Dipstick proteinuria 
 None/trace 1+ 2+ ≥3+ 
Men (N=215,103) N=206,267 N=6,652 N=1,622 N=562 
Cancer mortality     
 Model 1 1.0 1.45 (1.25-1.69) 1.42 (1.07-1.90) 1.87 (1.28-2.73) 
 Model 2 1.0 1.41 (1.21-1.65) 1.42 (1.06-1.91) 1.84 (1.24-2.72) 
CVD mortality     
 Model 1 1.0 2.60 (2.13-3.16) 2.75 (1.93-3.91) 5.15 (3.49-7.61) 
 Model 2 1.0 2.00 (1.63-2.45) 1.82 (1.26-2.61) 2.28 (1.49-3.51) 
Non-CVD/cancer 
mortality 
    
 Model 1 1.0 2.03 (1.74-2.38) 3.48 (2.78-4.37) 5.56 (4.24-7.29) 
 Model 2 1.0 1.71 (1.45-2.00) 2.70 (2.13-3.41) 3.35 (2.49-4.50) 
All-cause mortality     
 Model 1 1.0 1.85 (1.68-2.03) 2.34 (2.00-2.75) 3.67 (3.03-4.44) 
 Model 2 1.0 1.63 (1.48-1.80) 1.97 (1.68-2.32) 2.64 (2.15-3.23) 
Women (N=152,829) N=148,166 N=3,438 N=923 N=302 
Cancer mortality     
 Model 1 1.0 1.54 (1.12-2.11) 1.60 (0.90-2.82) 1.63 (0.68-3.93) 
 Model 2 1.0 1.49 (1.08-2.05) 1.51 (0.85-2.69) 1.64 (0.67-4.00) 
CVD mortality     
 Model 1 1.0 1.92 (1.26-2.92) 2.57 (1.37-4.81) 6.45 (3.45-12.07) 
 Model 2 1.0 1.52 (0.99-2.32) 1.47 (0.77-2.81) 3.80 (1.94-7.43) 
Non-CVD/cancer 
mortality 
    
 Model 1 1.0 2.48 (1.87-3.30) 4.16 (2.80-6.20) 8.11 (5.20-12.64) 
 Model 2 1.0 2.07 (1.55-2.75) 2.83 (1.86-4.30) 4.72 (2.91-7.67) 
All-cause mortality     
 Model 1 1.0 1.96 (1.62-2.36) 2.72 (2.03-3.63) 4.93 (3.53-6.89) 
 Model 2 1.0 1.71 (1.41-2.07) 2.04 (1.51-2.75) 3.46 (2.43-4.93) 
Model 1: adjusted for age 
Model 2: adjusted for age, total cholesterol, diabetes, cardiovascular disease, cancer, current 
smoker, systolic blood pressure, anti-hypertensive, body mass index and eGFR 
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Table 8 shows the HR for cause-specific mortality by eGFR and age (<60 and ≥ 60 
years). Adjusted HRs for mortality due to non-CVD/cancer was significantly increased as 
eGFR levels decreased in <60 years old, with eGFR of 75-89 ml/min/1.73m2 as a 
reference. Risk of cancer mortality was associated with the lowest eGFR levels (<45 
ml/min/1.73m2) in <60 years. In ≥60 years old, adjusted HRs for mortality due to CVD 
and non-CVD/cancer was significantly increased as eGFR levels decreased, with eGFR 
of 75-89 ml/min/1.73m2 as a reference.  
High proteinuria was consistently associated with all of CVD, cancer and non-
CVD/cancer mortality outcomes in <60 years, with robust dose-response relationship 
(Table 9). In ≥60 years old, high proteinuria was associated with risk of non-CVD/cancer 
mortality but not significantly in risk of CVD and cancer mortality. 
 
 
 
 
 
 
 
27 
 
 
 
Table 8. Hazard ratios (95%CI) for cause-specific mortality by eGFR and age 
 eGFR, ml/min/1.73m2 
 ≥105 90-104 75-89 60-74 45-59 <45 
Age<60 (N=339,855) N=87,358 N=133,768 N=94,769 N=22,406 N=1,310 N=244 
Cancer mortality       
 Model 1 1.37 (1.20-1.57) 1.09 (0.99-1.20) 1.0 0.91 (0.80-1.05) 0.91 (0.61-1.37) 3.11 (1.61-6.00) 
 Model 2 1.26 (1.10-1.45) 1.05 (0.96-1.15) 1.0 0.95 (0.83-1.09) 0.89 (0.59-1.35) 1.99 (1.00-3.96) 
CVD mortality       
 Model 1 1.13 (0.89-1.45) 1.00 (0.85-1.17) 1.0 1.04 (0.83-1.30) 2.07 (1.25-3.44) 7.63 (3.60-16.15) 
 Model 2 1.09 (0.86-1.39) 0.99 (0.84-1.17) 1.0 0.96 (0.77-1.21) 1.23 (0.73-2.07) 1.72 (0.76-3.89) 
Non-CVD/cancer mortality       
 Model 1 1.88 (1.63-2.16) 1.33 (1.19-1.49) 1.0 0.99 (0.83-1.17) 1.32 (0.81-2.14) 14.83 (9.85-22.33) 
 Model 2 1.67 (1.45-1.93) 1.27 (1.13-1.42) 1.0 0.99 (0.83-1.19) 1.08 (0.66-1.76) 4.72 (2.98-7.49) 
All-cause mortality       
 Model 1 1.51 (1.38-1.65) 1.15 (1.08-1.23) 1.0 0.96 (0.87-1.06) 1.23 (0.95-1.61) 7.40 (5.41-10.12) 
 Model 2 1.38 (1.26-1.52) 1.11 (1.04-1.08) 1.0 0.97 (0.88-1.07) 1.05 (0.80-1.37) 2.96 (2.10-4.16) 
Age>=60 (N=28,077) N=110 N=6,134 N=11,070 N=8,675 N=1,826 N=262 
Cancer mortality       
 Model 1 1.01 (0.42-2.44) 1.09 (0.95-1.25) 1.0 0.94 (0.83-1.06) 0.81 (0.66-1.01) 1.42 (0.94-2.14) 
 Model 2 0.81 (0.33-1.95) 1.02 (0.89-1.17) 1.0 0.99 (0.88-1.12) 0.88 (0.71-1.09) 1.38 (0.91-2.11) 
CVD mortality       
 Model 1 0.91 (0.23-3.68) 1.17 (0.96-1.44) 1.0 1.01 (0.85-1.20) 1.48 (1.17-1.87) 2.90 (1.95-4.31) 
 Model 2 0.77 (0.19-3.10) 1.14 (0.93-1.39) 1.0 0.99 (0.83-1.18) 1.35 (1.06-1.71) 2.20 (1.45-3.33) 
Non-CVD/cancer mortality       
 Model 1 1.40 (0.58-3.38) 1.18 (1.00-1.38) 1.0 0.92 (0.80-1.05) 1.22 (1.00-1.48) 3.62 (2.72-4.81) 
 Model 2 0.82 (0.34-2.01) 1.08 (0.92-1.27) 1.0 0.98 (0.85-1.13) 1.27 (1.04-1.56) 2.65 (1.96-3.59) 
All-cause mortality       
 Model 1 1.12 (0.63-1.97) 1.14 (1.04-1.25) 1.0 0.94 (0.87-1.02) 1.10 (0.98-1.24) 2.56 (2.10-3.12) 
 Model 2 0.82 (0.46-1.46) 1.07 (0.97-1.17) 1.0 0.98 (0.91-1.07) 1.13 (1.00-1.28) 2.10 (1.70-2.60) 
Model 1: adjusted for age  
Model 2: adjusted for age, total cholesterol, diabetes, cardiovascular disease, cancer, current smoker, systolic blood pressure, anti-hypertensive, body 
mass index and dipstick proteinuria 
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Table 9. Hazard ratios (95%CI) for cause-specific mortality by dipstick and age 
 Dipstick proteinuria 
 None/trace 1+ 2+ ≥3+ 
Age<60 (N=339,855) N=327,891 N=9,070 N=2,197 N=697 
Cancer mortality     
 Model 1 1.0 1.59 (1.33-1.90) 1.65 (1.16-2.36) 2.56 (1.63-4.02) 
 Model 2 1.0 1.52 (1.26-1.82) 1.58 (1.10-2.27) 2.38 (1.48-3.84) 
CVD mortality     
 Model 1 1.0 3.03 (2.38-3.85) 3.87 (2.53-5.91) 9.86 (6.45-15.09) 
 Model 2 1.0 2.19 (1.70-2.80) 2.31 (1.50-3.57) 4.03 (2.48-6.55) 
Non-CVD/cancer 
mortality 
    
 Model 1 1.0 2.19 (1.82-2.63) 4.07 (3.10-5.36) 7.45 (5.38-10.33) 
 Model 2 1.0 1.83 (1.52-2.21) 3.03 (2.28-4.02) 4.07 (2.81-5.90) 
All-cause mortality     
 Model 1 1.0 2.02 (1.80-2.26) 2.84 (2.34-3.44) 5.34 (4.27-6.68) 
 Model 2 1.0 1.76 (1.57-1.97) 2.29 (1.88-2.79) 3.55 (2.77-4.55) 
Age>=60 (N=28,077) N=26,542 N=1,020 N=348 N=167 
Cancer mortality     
 Model 1 1.0 1.39 (1.13-1.71) 1.31 (0.90-1.90) 1.30 (0.75-2.24) 
 Model 2 1.0 1.36 (1.10-1.68) 1.31 (0.89-1.92) 1.28 (0.73-2.23) 
CVD mortality     
 Model 1 1.0 1.91 (1.47-2.48) 1.98 (1.27-3.09) 3.13 (1.84-5.31) 
 Model 2 1.0 1.54 (1.18-2.02) 1.32 (0.83-2.08) 1.67 (0.96-2.92) 
Non-CVD/cancer 
mortality 
    
 Model 1 1.0 1.94 (1.58-2.38) 3.16 (2.38-4.20) 5.17 (3.72-7.18) 
 Model 2 1.0 1.63 (1.32-2.01) 2.40 (1.78-3.23) 3.42 (2.40-4.87) 
All-cause mortality     
 Model 1 1.0 1.69 (1.49-1.92) 2.07 (1.69-2.53) 2.94 (2.30-3.77) 
 Model 2 1.0 1.50 (1.32-1.71) 1.71 (1.38-2.10) 2.18 (1.68-2.82) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, 
current smoker, systolic blood pressure, anti-hypertensive, body mass index and eGFR 
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F. Association of CKD with finer cause of death 
 
Examining finer causes of death, low eGFR (<60 vs. ≥60 ml/min/1.73m2) was 
significantly associated with risks of death from oropharyngeal cancer, coronary heart 
disease, infectious disease, diabetes and renal failure (Figure 2). Given that diabetes and 
renal failure can be a cause of low eGFR, we repeated the analysis of eGFR and non-
CVD/cancer mortality after censoring death due to diabetes and renal failure and 
confirmed their significant positive relationship [HR 1.36 (95%CI 1.14-1.62) for eGFR 
<60 vs. ≥60 ml/min/1.73m2]. Unexpectedly, low eGFR was significantly associated with 
decreased risk of death from lung cancer and liver disease. 
Proteinuria (≥1+ vs. none/trace) was significantly associated with increased risk of 
death from cancer of various organs (i.e., stomach, liver, pancreas, lung and myeloma), 
both major CVDs (i.e., coronary heart disease and stroke), infectious disease, diabetes, 
liver disease and renal failure (Figure 3). Again we confirmed the significant association 
of proteinuria and non-CVD/cancer mortality after censoring death due to diabetes and 
renal failure [1.77 (1.54-2.02) for ≥1+ vs. none/trace dipstick proteinuria]. Largely 
consistent results were observed when we further adjusted for alchol intake, liver 
function marker (AST, ALT), seropositivity to viral hepatitis B and hepatitis C for liver 
cancer mortality [1.41 (1.03-1.94) for dipstick 1+ vs. negative/trace] and liver disease 
[1.38 (0.79-2.38)]. 
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Figure 5. Adjusted hazard ratios of cause-specific mortality for eGFR<60 ml/min/1.73m2 (vs. 
≥60) 
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Figure 6. Adjusted hazard ratios of cause-specific mortality for dipstick proteinuria (vs. 
none/trace)  
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G. Mortality risk by eGFR and dipstick proteinuria combination 
 
  The hazard ratio for each eGFR and dipstick proteinuria combination represents the 
point estimate from our cohort (Figure 6). As eGFR decreases and proteinuria increases, 
risk of CVD and non-CVD mortality was increased (HR 4.73 for CVD mortality and 9.07 
for non-CVD/cancer mortality in the lowest eGFR and highest proteinuria group). For 
cancer mortality, risk increases as proteinuria increases in the highest eGFR and lowest 
eGFR groups. 
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 All-cause mortality   CVD mortality 
 None/ 
trace 
+1 +2 ≥+3   None/ 
trace 
+1 +2 ≥+3 
eGFR 
≥90 
Ref 1.71* 2.45* 3.59*  eGFR 
≥90 
Ref 1.91* 1.83 3.45* 
eGFR 
60-89 
0.89* 1.50* 1.55* 2.32*  eGFR 
60-89 
0.95 1.86* 1.70* 3.16* 
eGFR 
45-59 
1.08 1.21 1.91* 2.62*  eGFR 
45-59 
1.49* 1.76* 1.49 1.44 
eGFR 
<45 
1.79* 4.21* 4.24* 5.31*  eGFR 
<45 
1.84* 4.89* 3.58* 4.73* 
     
 Cancer mortality   Non-CVD/cancer mortality 
 None/ 
trace 
+1 +2 ≥+3   None/ 
trace 
+1 +2 ≥+3 
eGFR 
≥90 
Ref 1.50* 1.92* 3.61*  eGFR 
≥90 
Ref 1.85* 3.28* 3.51* 
eGFR 
60-89 
0.94 1.35* 1.12 1.11  eGFR 
60-89 
0.80* 1.48* 1.89* 3.16* 
eGFR 
45-59 
0.75 1.00 1.08 1.82  eGFR 
45-59 
1.27* 1.11 3.23* 4.17* 
eGFR 
<45 
1.23 1.79 2.30* 1.53  eGFR 
<45 
2.55* 6.83* 6.95* 9.07* 
 
Figure 7. Adjusted hazard ratio of cause-specific mortality by combined eGFR with dipstick 
proteinuria 
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H. Morbidity risk by eGFR 
 
i. Cancer incidence by eGFR  
 
Table 10 shows HRs of total and site-specific cancer incidence by eGFR. Crude HRs 
for total cancer incidence was significantly increased as eGFR levels decreased, with 
eGFR of 75-89 ml/min/1.73m2 as a reference. After adjusting for the potential 
confounders, the highest and lowest eGFR were associated with higher risk of incidence 
of cancer compared to the reference group, but risk of cancer incidence was lowest at 
eGFR 45-50 ml/min/1.73m2. Examining finer causes of cancer incidence, lowest eGFR 
was significantly associated with increased risk of cancer from urinary tract, multiple 
myeloma and leukemia in both genders, and only ovary cancer for women. 
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Table 10. Hazard ratios (95%CI) for site-specific cancer incidence by eGFR, Korean Heart Study, N=233,219 
 eGFR, ml/min/1.73m2 
 ≥105 90-104 75-89 60-74 45-59 <45 
 N=41,032 N=91,204 N=74,913 N=23,646 N=2,116 N=308 
All cancers       
 Case 1,808 5,230 5,088 2,095 263 53 
 Crude 0.64 (0.61-0.68) 0.85 (0.81-0.88) 1.0 1.31 (1.24-1.38) 1.90 (1.68-2.15) 3.01 (2.29-3.94) 
 Model1 1.16 (1.10-1.23) 1.04 (1.00-1.08) 1.0 0.94 (0.89-0.99) 0.94 (0.83-1.06) 1.72 (1.31-2.26) 
 Model2 1.13 (1.07-1.19) 1.02 (0.98-1.06) 1.0 0.95 (0.90-1.00) 0.91 (0.80-1.02) 1.45 (1.12-1.88) 
Oropharinx       
 Case 22 68 80 39 8 0 
 Crude 0.50 (0.31-0.80) 0.70 (0.51-0.97) 1.0 1.53 (1.05-2.25) 3.59 (1.73-7.42) - 
 Model1 1.10 (0.67-1.82) 0.91 (0.65-1.26) 1.0 1.10 (0.75-1.63) 1.82 (0.87-3.84) - 
 Model2 1.09 (0.67-1.77) 0.89 (0.65-1.23) 1.0 1.03 (0.70-1.50) 1.72 (0.85-3.49) - 
Oesophagus       
 Case 8 54 72 26 3 0 
 Crude 0.20 (0.10-0.42) 0.62 (0.43-0.88) 1.0 1.14 (0.73-1.79) 1.51 (0.48-5.12) - 
 Model1 1.15 (0.53-2.49) 1.06 (0.74-1.52) 1.0 0.60 (0.40-0.97) 0.50 (0.18-1.37) - 
 Model2 0.91 (0.42-1.96) 1.02 (0.71-1.45) 1.0 0.68 (0.44-1.06) 0.56 (0.20-1.55) - 
Stomach       
 Case 260 912 968 361 47 8 
 Crude 0.49 (0.43-0.56) 0.78 (0.71-0.85) 1.0 1.17 (1.04-1.33) 1.75 (1.31-2.35) 2.29 (1.14-4.60) 
 Model1 1.14 (0.98-1.31) 1.03 (0.94-1.12) 1.0 0.81 (0.72-0.92) 0.82 (0.61-1.10) 1.21 (0.60-2.44) 
 Model2 1.09 (0.95-1.26) 1.00 (0.92-1.10) 1.0 0.83 (0.73-0.93) 0.78 (0.58-1.04) 1.22 (0.65-2.32) 
Colon       
 Case 104 431 417 211 34 4 
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 Crude 0.45 (0.37-0.56) 0.85 (0.75-0.98) 1.0 1.60 (1.35-1.88) 2.94 (2.07-4.17) 2.68 (1.00-7.17) 
 Model1 1.14 (0.91-1.44) 1.15 (1.01-1.32) 1.0 1.04 (0.88-1.23) 1.19 (0.84-1.70) 1.26 (0.47-3.39) 
 Model2 1.15 (0.91-1.44) 1.15 (1.01-1.31) 1.0 1.04 (0.88-1.22) 1.07 (0.76-1.52) 0.97 (0.36-2.66) 
Rectum       
 Case 76 310 313 133 15 1 
 Crude 0.44 (0.35-0.57) 0.82 (0.70-0.96) 1.0 1.34 (1.09-1.64) 1.72 (1.02-2.89) 0.89 (0.12-6.31) 
 Model1 1.00 (0.77-1.31) 1.07 (0.91-1.26) 1.0 0.92 (0.75-1.13) 0.79 (0.47-1.33) 0.47 (0.07-3.34) 
 Model2 0.98 (0.76-1.28) 1.04 (0.89-1.21) 1.0 0.87 (0.71-1.07) 0.84 (0.52-1.34) 0.64 (0.15-2.61) 
Liver       
 Case 144 528 498 192 19 3 
 Crude 0.53 (0.44-0.64) 0.88 (0.78-0.99) 1.0 1.21 (1.03-1.43) 1.37 (0.87-2.17) 1.66 (0.53-5.16) 
 Model1 1.25 (1.03-1.53) 1.16 (1.02-1.32) 1.0 0.85 (0.72-1.00) 0.65 (0.41-1.04) 0.89 (0.29-2.79) 
 Model2 1.13 (0.93-1.38) 1.11 (0.98-1.25) 1.0 0.83 (0.70-0.98) 0.62 (0.40-0.96) 0.88 (0.35-2.18) 
Gallbladder       
 Case 9 52 50 29 4 2 
 Crude 0.33 (0.16-0.66) 0.86 (0.58-1.26) 1.0 1.83 (1.16-2.89) 2.87 (1.04-7.95) 10.88 (2.65-44.70) 
 Model1 0.92 (0.44-1.95) 1.20 (0.81-1.79) 1.0 1.07 (0.67-1.71) 0.94 (0.33-2.62) 4.15 (1.00-17.21) 
 Model2 0.97 (0.47-1.98) 1.22 (0.83-1.80) 1.0 1.11 (0.71-1.73) 0.80 (0.29-2.25) 3.76 (0.88-15.99) 
Bile duct       
 Case 9 83 100 39 7 2 
 Crude 0.16 (0.08-0.32) 0.68 (0.51-0.91) 1.0 1.23 (0.85-1.78) 2.54 (1.18-5.47) 5.50 (1.36-22.30) 
 Model1 0.61 (0.30-1.24) 1.03 (0.77-1.39) 1.0 0.71 (0.49-1.03) 0.80 (0.37-1.74) 2.07 (0.51-8.42) 
 Model2 0.79 (0.41-1.51) 1.09 (0.82-1.46) 1.0 0.70 (0.49-1.01) 0.77 (0.37-1.59) 1.95 (0.47-8.09) 
Pancreas       
 Case 35 127 155 84 11 0 
 Crude 0.41 (0.29-0.60) 0.68 (0.54-0.86) 1.0 1.70 (1.31-2.22) 2.54 (1.38-4.69) - 
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 Model1 1.11 (0.75-1.64) 0.93 (0.74-1.19) 1.0 1.07 (0.82-1.40) 0.96 (0.52-1.79) - 
 Model2 1.11 (0.75-1.63) 0.94 (0.74-1.19) 1.0 1.04 (0.80-1.36) 0.91 (0.50-1.65) - 
Lung       
 Case 109 508 567 265 26 9 
 Crude 0.35 (0.28-0.43) 0.74 (0.66-0.83) 1.0 1.47 (1.27-1.70) 1.65 (1.11-2.44) 4.45 (2.31-8.61) 
 Model1 1.24 (1.00-1.54) 1.11 (0.98-1.25) 1.0 0.87 (0.75-1.00) 0.55 (0.37-0.82) 1.74 (0.90-3.37) 
 Model2 1.17 (0.94-1.44) 1.08 (0.96-1.21) 1.0 0.92 (0.80-1.06) 0.64 (0.44-0.92) 1.33 (0.67-2.63) 
Breast*       
 Case 233 345 266 116 13 1 
 Crude 1.24 (1.04-1.48) 1.01 (0.86-1.18) 1.0 1.11 (0.89-1.38) 1.01 (0.58-1.77) 0.70 (0.10-5.01) 
 Model1 1.20 (1.00-1.45) 1.00 (0.85-1.17) 1.0 1.13 (0.91-1.42) 1.05 (0.60-1.85) 0.72 (0.10-5.17) 
 Model2 1.20 (1.00-1.45) 1.00 (0.85-1.17) 1.0 1.14 (0.91-1.42) 1.04 (0.59-1.83) 0.62 (0.08-4.54) 
Ovary*       
 Case 33 61 49 25 2 1 
 Crude 0.97 (0.62-1.50) 0.97 (0.67-1.41) 1.0 1.29 (0.80-2.10) 0.84 (0.20-3.45) 3.79 (0.52-27.47) 
 Model1 1.24 (0.77-2.01) 1.06 (0.73-1.56) 1.0 1.13 (0.69-1.84) 0.65 (0.16-2.69) 3.05 (0.42-22.23) 
 Model2 1.25 (0.77-2.02) 1.07 (0.73-1.57) 1.0 1.11 (0.68-1.82) 0.61 (0.15-2.55) 2.43 (0.31-18.79) 
Urinary tract       
 Case 70 256 291 152 24 12 
 Crude 0.43 (0.33-0.56) 0.72 (0.61-0.86) 1.0 1.65 (1.36-2.01) 2.99 (1.97-4.53) 11.50 (6.45-20.48) 
 Model1 0.98 (0.75-1.30) 0.95 (0.80-1.12) 1.0 1.18 (0.97-1.44) 1.50 (0.98-2.30) 6.55 (3.66-11.73) 
 Model2 1.00 (0.76-1.32) 0.96 (0.81-1.14) 1.0 1.16 (0.95-1.41) 1.41 (0.92-2.16) 4.91 (2.62-9.20) 
Brain       
 Case 24 61 54 26 1 1 
 Crude 0.81 (0.50-1.31) 0.93 (0.65-1.35) 1.0 1.51 (0.95-2.42) 0.66 (0.09-4.79) 5.03 (0.70-36.35) 
 Model1 1.53 (0.91-2.58) 1.16 (0.80-1.68) 1.0 1.11 (0.69-1.78) 0.34 (0.05-2.48) 2.93 (0.40-21.31) 
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 Model2 1.40 (0.84-2.34) 1.12 (0.78-1.60) 1.0 1.07 (0.68-1.69) 0.56 (0.13-2.32) 1.95 (0.25-15.45) 
Non-Hodgkin’s lymphoma       
 Case 33 105 103 46 4 0 
 Crude 0.59 (0.40-0.87) 0.85 (0.64-1.11) 1.0 1.40 (0.99-1.98) 1.38 (0.51-3.76) - 
 Model1 0.96 (0.63-1.45) 0.99 (0.76-1.31) 1.0 1.13 (0.79-1.61) 0.88 (0.32-2.43) - 
 Model2 0.93 (0.62-1.40) 1.00 (0.76-1.30) 1.0 1.09 (0.77-1.54) 0.97 (0.39-2.42) - 
Multiple myeloma       
 Case 6 24 48 17 4 4 
 Crude 0.23 (0.10-0.53) 0.41 (0.25-0.67) 1.0 1.11 (0.64-1.93) 2.98 (1.08-8.27) 23.33 (8.41-64.71) 
 Model1 0.62 (0.25-1.51) 0.57 (0.35-0.94) 1.0 0.71 (0.40-1.24) 1.16 (0.41-3.28) 10.60 (3.75-29.98) 
 Model2 0.61 (0.25-1.49) 0.61 (0.37-0.99) 1.0 0.71 (0.41-1.24) 1.42 (0.58-3.44) 5.16 (1.56-17.05) 
Leukemia       
 Case 22 77 69 19 2 2 
 Crude 0.59 (0.36-0.95) 0.93 (0.67-1.28) 1.0 0.86 (0.52-1.43) 1.03 (0.25-4.21) 8.02 (1.97-32.73) 
 Model1 1.17 (0.70-1.95) 1.17 (0.84-1.62) 1.0 0.61 (0.37-1.03) 0.50 (0.12-2.08) 4.47 (1.09-18.37) 
 Model2 1.11 (0.66-1.85) 1.22 (0.88-1.69) 1.0 0.62 (0.37-1.04) 0.49 (0.12-2.02) 4.88 (1.15-20.73) 
* Only Women 
† Only men 
Model 1: unadjusted 
Model 2: adjusted for age and gender 
Model 3: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, current smoker, systolic blood pressure, anti-hypertensive, body 
mass index and dipstick proteinuria 
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ii. CVD incidence by eGFR 
 
Crude HRs for CVD incidence including ischemic heart diseases and total stroke were 
significantly increased as eGFR levels decreases, with eGFR of 75-89 ml/min/1.73m2 as 
a reference (Table 11). After adjusting for the potential confounders, eGFR categories 
below 60 ml/min/1.73m2 were significantly associated with higher CVD incidence. High 
eGFR was associated with lower risk of CVD including ischemic heart disease and total 
stroke compared to the reference group in the crude model but showed higher risk once 
age and gender were taken into account. 
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Table 11. Hazard ratios (95%CI) for CVD incidence by eGFR 
 eGFR, ml/min/1.73m2 
 ≥105 90-104 75-89 60-74 45-59 <45 
 N=41,032 N=91,204 N=74,913 N=23,646 N=2,116 N=308 
CVD       
 Case 5,993 16,569 15,367 6,154 765 198 
 Crude 0.69 (0.67-0.71) 0.88 (0.86-0.90) 1.0 1.30 (1.26-1.34) 1.94 (1.81-2.09) 4.60 (4.00-5.30) 
 Model1 1.02 (0.99-1.06) 1.01 (0.99-1.03) 1.0 1.04 (1.01-1.07) 1.18 (1.10-1.27) 3.01 (2.62-3.47) 
 Model2 1.03 (1.00-1.06) 1.01 (0.99-1.04) 1.0 1.01 (0.98-1.03) 1.05 (0.97-1.13) 1.97 (1.70-2.28) 
Coronary heart disease       
 Case 377 1,647 1,827 944 154 29 
 Crude 0.37 (0.33-0.42) 0.74 (0.69-0.79) 1.0 1.64 (1.51-1.77) 3.11 (2.63-3.66) 4.49 (3.11-6.48) 
 Model1 0.86 (0.76-0.96) 0.97 (0.91-1.04) 1.0 1.12 (1.03-1.21) 1.40 (1.18-1.66) 2.34 (1.62-3.38) 
 Model2 0.90 (0.80-1.01) 1.00 (0.93-1.07) 1.0 1.05 (0.97-1.14) 1.18 (1.00-1.40) 1.46 (1.00-2.14) 
Stroke       
 Case 608 2,251 2,508 1,275 208 51 
 Crude 0.44 (0.40-0.48) 0.74 (0.70-0.78) 1.0 1.61 (1.51-1.73) 3.05 (2.65-3.52) 5.94 (4.50-7.83) 
 Model1 1.15 (1.04-1.26) 1.01 (0.95-1.07) 1.0 1.00 (0.94-1.08) 1.12 (0.97-1.29) 2.57 (1.95-3.40) 
 Model2 1.13 (1.03-1.25) 1.00 (0.95-1.06) 1.0 0.97 (0.91-1.04) 0.98 (0.84-1.13) 1.60 (1.20-2.14) 
Model 1: unadjusted 
Model 2: adjusted for age and gender 
Model 3: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, current smoker, systolic blood pressure, anti-hypertensive, body 
mass index and dipstick proteinuria 
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iii. Non-CVD/cancer disease incidence 
 
 Crude HRs for viral hepatitis, pneumonia, diabetes, Parkinson’s disease, COPD and 
pulmonary disease were significantly increased as eGFR levels decreased with eGFR of 
75-89 ml/min/1.73m2 as a reference (Table 12). However, the association of low eGFR 
with incidence of COPD, diabetes, Parkinson’s disease, and pulmonary disease was 
attenuated after adjusting for the potential confounders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
 
 
Table 12. Hazard ratios (95%CI) for Non-CVD/cancer incidence by eGFR 
 eGFR, ml/min/1.73m2 
 ≥105 90-104 75-89 60-74 45-59 <45 
 N=41,032 N=91,204 N=74,913 N=23,646 N=2,116 N=308 
Infectious disease       
 Case 39,943 88,743 72,893 22,922 2,041 293 
 Crude 0.97 (0.95-0.99) 0.99 (0.97-1.00) 1.0 1.01 (0.98-1.03) 1.03 (0.95-1.11) 0.92 (0.76-1.12) 
 Model1 0.99 (0.97-1.01) 0.99 (0.98-1.01) 1.0 0.98 (0.96-1.01) 0.96 (0.90-1.04) 0.89 (0.74-1.08) 
 Model2 0.99 (0.97-1.01) 1.00 (0.98-1.01) 1.0 0.99 (0.96-1.01) 0.97 (0.90-1.04) 0.92 (0.76-1.12) 
Viral hepatitis       
 Case 2,369 5,481 4,578 1,520 141 33 
 Crude 0.96 (0.90-1.01) 0.97 (0.93-1.01) 1.0 1.07 (1.00-1.14) 1.13 (0.93-1.36) 1.78 (1.17-2.70) 
 Model1 1.05 (0.99-1.12) 1.00 (0.96-1.05) 1.0 1.02 (0.95-1.09) 1.03 (0.85-1.24) 1.66 (1.09-2.52) 
 Model2 1.05 (0.99-1.12) 1.00 (0.96-1.05) 1.0 1.02 (0.95-1.09) 1.01 (0.83-1.23) 1.59 (1.03-2.45) 
Pneumonia       
 Case 3,176 8,186 7,292 2,996 366 61 
 Crude 0.76 (0.73-0.80) 0.92 (0.89-0.95) 1.0 1.33 (1.27-1.39) 1.90 (1.70-2.13) 2.52 (1.93-3.27) 
 Model1 1.11 (1.06-1.17) 1.05 (1.02-1.09) 1.0 1.03 (0.99-1.08) 1.08 (0.97-1.21) 1.64 (1.26-2.13) 
 Model2 1.09 (1.04-1.14) 1.04 (1.01-1.08) 1.0 1.04 (1.00-1.09) 1.09 (0.97-1.22) 1.47 (1.12-1.93) 
Diabetes       
 Case 4,536 13,642 13,049 5,477 676 127 
 Crude 0.61 (0.59-0.64) 0.84 (0.82-0.86) 1.0 1.35 (1.30-1.40) 1.85 (1.69-2.03) 2.58 (2.09-3.20) 
 Model1 1.09 (1.05-1.13) 1.03 (1.00-1.06) 1.0 1.00 (0.96-1.03) 0.95 (0.87-1.04) 1.50 (1.21-1.86) 
 Model2 1.20 (1.15-1.24) 1.08 (1.05-1.11) 1.0 0.94 (0.91-0.97) 0.78 (0.71-0.86) 0.81 (0.65-1.00) 
Renal failure       
 Case 143 510 601 549 236 211 
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 Crude 0.44 (0.36-0.53) 0.71 (0.63-0.80) 1.0 2.95 (2.62-3.32) 14.54 (12.42-17.02) 177.71 (149.65-211.03) 
 Model1 0.74 (0.61-0.89) 0.84 (0.74-0.95) 1.0 2.33 (2.07-2.64) 8.92 (7.55-10.54) 113.55 (94.75-136.09) 
 Model2 0.72 (0.60-0.88) 0.84 (0.75-0.95) 1.0 2.12 (1.88-2.40) 6.09 (5.13-7.22) 32.28 (26.28-39.64) 
Parkinson       
 Case 62 358 462 301 77 6 
 Crude 0.23 (0.18-0.31) 0.63 (0.55-0.73) 1.0 1.98 (1.71-2.31) 5.74 (4.46-7.40) 3.19 (1.32-7.71) 
 Model1 0.98 (0.73-1.31) 0.98 (0.85-1.13) 1.0 1.05 (0.90-1.22) 1.51 (1.17-1.96) 0.99 (0.41-2.38) 
 Model2 0.97 (0.72-1.30) 0.98 (0.85-1.13) 1.0 1.05 (0.90-1.22) 1.49 (1.14-1.93) 0.86 (0.35-2.11) 
COPD       
 Case 2,132 7,037 6,973 3,018 390 44 
 Crude 0.55 (0.52-0.58) 0.82 (0.79-0.85) 1.0 1.38 (1.32-1.45) 2.00 (1.78-2.24) 1.75 (1.26-2.43) 
 Model1 1.09 (1.03-1.15) 1.04 (1.00-1.08) 1.0 0.95 (0.90-0.99) 0.88 (0.78-0.99) 0.92 (0.66-1.27) 
 Model2 1.07 (1.01-1.13) 1.03 (0.99-1.07) 1.0 0.96 (0.91-1.01) 0.90 (0.80-1.01) 0.89 (0.63-1.24) 
Pulmonary disease       
 Case 76 230 294 157 20 7 
 Crude 0.47 (0.36-0.60) 0.64 (0.54-0.77) 1.0 1.62 (1.33-1.98) 2.44 (1.54-3.89) 6.96 (3.29-14.73) 
 Model1 1.31 (0.99-1.72) 0.89 (0.75-1.07) 1.0 1.03 (0.84-1.26) 0.94 (0.59-1.51) 3.15 (1.48-6.68) 
 Model2 1.25 (0.95-1.66) 0.88 (0.73-1.05) 1.0 1.04 (0.85-1.28) 0.94 (0.59-1.51) 2.20 (0.99-4.89) 
Liver disease       
 Case 8,717 21,785 18,508 6,361 612 84 
 Crude 0.85 (0.83-0.88) 0.96 (0.94-0.98) 1.0 1.11 (1.07-1.14) 1.21 (1.11-1.33) 1.19 (0.93-1.53) 
 Model1 1.08 (1.05-1.11) 1.05 (1.03-1.07) 1.0 0.98 (0.95-1.02) 0.94 (0.86-1.03) 0.98 (0.76-1.26) 
 Model2 1.12 (1.09-1.15) 1.07 (1.05-1.09) 1.0 0.95 (0.92-0.99) 0.87 (0.80-0.96) 0.89 (0.69-1.14) 
Model 1: unadjusted 
Model 2: adjusted for age and gender 
Model 3: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, current smoker, systolic blood pressure, anti-hypertensive, body mass index and 
dipstick proteinuria 
44 
 
 
 
I. Morbidity risk by dipstick proteinuria 
 
i. Cancer incidence by dipstick proteinuria 
 
Table 13 shows HR for total and site-specific cancer incidence by dipstick proteinuria. 
In contrast to eGFR, high proteinuria was associated with total cancer incidence, with 
robust dose-response relationship. For total incidence of cancer, outcomes significantly 
increased even at 1+ proteinuria group. When examining site-specific cancer outcomes, 
positive proteinuria was significantly associated with increased risk of cancer from 
oesophagus, stomach, rectum, liver, lung, urinary tract, myeloma in both genders, and 
ovarian cancer in women. High proteinuria was significantly associated with incidence of 
cancer due to much broader causes, as compared to low eGFR. 
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Table 13. Hazard ratios (95%CI) for site-specific cancer incidence by dipstick proteinuria 
 Dipstick proteinuria 
 None/trace 1+ 2+ ≥3+ 
 N=224,973 N=6,331 N=1,421 N=494 
All cancers     
 Case 13,834 513 128 62 
 Crude 1.0 1.31 (1.20-1.44) 1.55 (1.31-1.85) 2.13 (1.66-2.73) 
 Model1 1.0 1.25 (1.15-1.37) 1.33 (1.11-1.58) 1.66 (1.30-2.14) 
 Model2 1.0 1.23 (1.13-1.34) 1.39 (1.18-1.63) 1.68 (1.32-2.14) 
Oropharinx     
 Case 202 13 2 0 
 Crude 1.0 2.27 (1.29-3.97) 1.65 (0.41-6.63) - 
 Model1 1.0 1.94 (1.11-3.40) 1.24(0.31-4986) - 
 Model2 1.0 1.67 (0.95-2.95) 1.06 (0.26-4.29) - 
Oesophagus     
 Case 149 13 1 0 
 Crude 1.0 3.10 (1.76-5.46) 1.11 (0.16-7.92) - 
 Model1 1.0 2.29 (1.30-4.04) 0.65 (0.09-4.65) - 
 Model2 1.0 2.04 (1.14-3.63) 1.17 (0.29-4.77) - 
Stomach     
 Case 2,416 112 18 10 
 Crude 1.0 1.64 (1.35-1.98) 1.24 (0.78-1.97) 1.92 (1.03-3.57) 
 Model1 1.0 1.42 (1.17-1.71) 0.94 (0.59-1.49) 1.29 (0.69-2.40) 
 Model2 1.0 1.37 (1.13-1.65) 1.04 (0.68-1.60) 1.28 (0.70-2.35) 
Colon     
 Case 1,152 32 11 6 
 Crude 1.0 0.98 (0.69-1.39) 1.59 (0.88-2.87) 2.42 (1.08-5.40) 
 Model1 1.0 0.86 (0.61-1.23) 1.19 (0.66-2.16) 1.60 (0.72-3.57) 
 Model2 1.0 0.88 (0.63-1.23) 1.33 (0.78-2.26) 1.40 (0.62-3.18) 
Rectum     
 Case 797 37 12 2 
 Crude 1.0 1.64 (1.18-2.28) 2.50 (1.42-4.43) 1.16 (0.29-4.66) 
 Model1 1.0 1.45 (1.04-2.02) 1.94 (1.09-3.42) 0.80 (0.20-3.19) 
 Model2 1.0 1.45 (1.06-1.99) 1.70 (0.95-3.03) 1.44 (0.53-3.91) 
Liver     
 Case 1,303 58 14 9 
 Crude 1.0 1.57 (1.21-2.04) 1.78 (1.05-3.01) 3.20 (1.66-6.16) 
 Model1 1.0 1.34 (1.03-1.75) 1.34 (0.79-2.26) 2.14 (1.11-4.13) 
 Model2 1.0 1.29 (0.99-1.67) 1.42 (0.86-2.33) 2.50 (1.31-4.75) 
Gallbladder     
46 
 
 
 
 Case 137 8 1 0 
 Crude 1.0 2.07 (1.01-4.21) 1.19 (0.17-8.54) - 
 Model1 1.0 1.93 (0.94-3.94) 0.92 (0.13-6.58) - 
 Model2 1.0 1.60 (0.78-3.29) 0.63 (0.09-4.63) - 
Bile duct     
 Case 225 13 2 0 
 Crude 1.0 2.05 (1.17-3.58) 1.47 (0.37-5.93) - 
 Model1 1.0 1.69 (0.97-2.96) 0.99 (0.25-4.00) - 
 Model2 1.0 1.47 (0.84-2.59) 0.76 (0.18-3.10) - 
Pancreas     
 Case 390 17 4 1 
 Crude 1.0 1.53 (0.94-2.49) 1.70 (0.64-4.56) 1.18 (0.17-8.42) 
 Model1 1.0 1.35 (0.83-2.20) 1.26 (0.47-3.39) 0.76 (0.11-5.40) 
 Model2 1.0 1.17 (0.72-1.92) 1.07 (0.40-2.89) 0.69 (0.10-4.97) 
Lung     
 Case 1,387 73 15 9 
 Crude 1.0 1.85 (1.47-2.35) 1.80 (1.08-2.99) 2.99 (1.55-5.77) 
 Model1 1.0 1.54 (1.22-1.95) 1.23 (0.74-2.05) 1.71 (0.89-3.29) 
 Model2 1.0 1.53 (1.21-1.94) 1.20 (0.72-2.01) 2.21 (1.23-3.98) 
Breast*     
 Case 938 26 7 3 
 Crude 1.0 1.26 (0.86-1.87) 1.46 (0.69-3.07) 1.58 (0.51-4.91) 
 Model1 1.0 1.26 (0.86-1.87) 1.47 (0.70-3.10) 1.60 (0.51-4.97) 
 Model2 1.0 1.29 (0.87-1.90) 1.55 (0.73-3.27) 1.84 (0.58-5.83) 
Ovary*     
 Case 159 9 3 0 
 Crude 1.0 2.56 (1.31-5.00) 3.65 (1.17-11.45) - 
 Model1 1.0 2.55 (1.30-4.99) 3.50 (1.12-10.98) - 
 Model2 1.0 2.55 (1.30-5.02) 3.31 (1.01-10.78) - 
Urinary tract     
 Case 744 37 18 6 
 Crude 1.0 1.76 (1.26-2.44) 4.04 (2.53-6.45) 3.70 (1.66-8.27) 
 Model1 1.0 1.49 (1.07-2.07) 3.00 (1.88-4.79) 2.43 (1.09-5.43) 
 Model2 1.0 1.42 (1.02-1.98) 2.45 (1.51-3.99) 1.57 (0.67-3.66) 
Brain     
 Case 159 5 2 1 
 Crude 1.0 1.11 (0.45-2.70) 2.08 (0.52-8.38) 2.90 (0.41-20.72) 
 Model1 1.0 1.02 (0.42-2.48) 1.73 (0.43-6.97) 2.22 (0.31-15.86) 
 Model2 1.0 1.22 (0.54-2.76) 1.73 (0.42-7.13) 2.13 (0.28-16.43) 
Non-Hodgkin’s 
lymphoma 
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 Case 284 6 0 1 
 Crude 1.0 0.74 (0.33-1.67) - 1.64 (0.23-11.69) 
 Model1 1.0 0.68 (0.30-1.52) - 1.29 (0.18-9.19) 
 Model2 1.0 0.64 (0.28-1.44) - 1.38 (0.19-9.93) 
Multiple myeloma     
 Case 90 8 2 3 
 Crude 1.0 3.12 (1.51-6.44) 3.69 (0.91-14.98) 15.29 (4.84-48.31) 
 Model1 1.0 2.70 (1.31-5.57) 2.66 (0.65-10.81) 9.39 (2.96-29.83) 
 Model2 1.0 2.42 (1.16-5.04) 1.89 (0.44-8.08) 4.61 (1.22-17.37) 
Leukemia     
 Case 184 6 1 0 
 Crude 1.0 1.15 (0.51-2.60) 0.90 (0.13-6.45) - 
 Model1 1.0 1.06 (0.47-2.39) 0.74 (0.10-5.31) - 
 Model2 1.0 1.01 (0.45-2.30) 0.61 (0.08-4.50) - 
 * Only Women 
Model 1: unadjusted 
Model 2: adjusted for age and gender 
Model 3: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, current 
smoker, systolic blood pressure, anti-hypertensive, body mass index and eGFR 
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ii. CVD incidence by dipstick proteinuria 
 
  In contrast to eGFR, high proteinuria was consistently associated with CVD including 
ischemic heart disease and total stroke, with robust dose-response relationship (Table 14). 
However, the association of highest proteinuria group with incidence of ischemic heart 
diseases was attenuated after adjusting for the potential confounders. 
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Table 14. Hazard ratios (95%CI) for CVD incidence by dipstick proteinuria  
 Dipstick proteinuria 
 None/trace 1+ 2+ ≥3+ 
 N=224,973 N=6,331 N=1,421 N=494 
CVD     
 Case 42,773 1,568 464 241 
 Crude 1.0 1.34 (1.27-1.40) 1.93 (1.76-2.12) 3.18 (2.80-3.60) 
 Model1 1.0 1.29 (1.22-1.35) 1.73 (1.57-1.89) 2.63 (2.32-2.99) 
 Model2 1.0 1.16 (1.10-1.22) 1.39 (1.27-1.53) 1.76 (1.54-2.01) 
Coronary heart disease     
 Case 4,615 241 82 40 
 Crude 1.0 1.86 (1.63-2.11) 3.00 (2.41-3.74) 4.06 (2.98-5.55) 
 Model1 1.0 1.63 (1.43-1.85) 2.27 (1.83-2.83) 2.70 (1.98-3.69) 
 Model2 1.0 1.22 (1.07-1.39) 1.37 (1.09-1.71) 1.34 (0.97-1.86) 
Stroke     
 Case 6,418 321 108 54 
 Crude 1.0 1.78 (1.59-1.99) 2.86 (2.36-3.46) 3.99 (3.06-5.22) 
 Model1 1.0 1.62 (1.45-1.82) 2.20 (1.82-2.66) 2.67 (2.04-3.49) 
 Model2 1.0 1.16 (1.04-1.30) 1.54 (1.26-1.86) 1.50 (1.13-1.98) 
Model 1: unadjusted 
Model 2: adjusted for age and gender 
Model 3: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, current 
smoker, systolic blood pressure, anti-hypertensive, body mass index and eGFR 
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iii. Non-CVD/cancer incidence by dipstick proteinuria 
   
Crude HRs for incidence of pneumonia, diabetes, renal failure, Parkinson’s and 
pulmonary diseases were significantly increased as higher proteinuria (Table 15). After 
adjusting for the potential confounders, the association of high proteinuria with diabetes 
Parkinson’s disease, COPD and pulmonary diseases was still remained, but its 
association of Parkinson’s disease was attenuated.  
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Table 15. Hazard ratios (95%CI) for Non-CVD/cancer incidence by dipstick proteinuria 
 Dipstick proteinuria 
 None/trace 1+ 2+ ≥3+ 
 N=224,973 N=6,331 N=1,421 N=494 
Infectious disease     
 Case 218,863 6,131 1,368 473 
 Crude 1.0 1.00 (0.96-1.04) 0.93 (0.86-1.02) 0.94 (0.82-1.07) 
 Model1 1.0 1.00 (0.97-1.04) 0.93 (0.85-1.01) 0.93 (0.81-1.06) 
 Model2 1.0 1.01 (0.97-1.05) 0.94 (0.86-1.02) 0.96 (0.84-1.10) 
Viral hepatitis     
 Case 13,533 445 106 38 
 Crude 1.0 1.15 (1.03-1.28) 1.26 (1.01-1.58) 1.15 (0.78-1.70) 
 Model1 1.0 1.12 (1.01-1.25) 1.22 (0.98-1.53) 1.10 (0.74-1.63) 
 Model2 1.0 1.10 (0.99-1.23) 1.17 (0.93-1.46) 1.02 (0.68-1.53) 
Pneumonia     
 Case 21,167 673 164 73 
 Crude 1.0 1.13 (1.04-1.23) 1.27 (1.08-1.50) 1.66 (1.31-2.12) 
 Model1 1.0 1.12 (1.03-1.22) 1.16 (0.98-1.37) 1.42 (1.11-1.80) 
 Model2 1.0 1.12 (1.03-1.22) 1.16 (0.98-1.37) 1.36 (1.06-1.74) 
Diabetes     
 Case 34,876 1,846 558 227 
 Crude 1.0 1.96 (1.86-2.06) 2.76 (2.50-3.05) 3.11 (2.64-3.65) 
 Model1 1.0 1.91 (1.81-2.01) 2.47 (2.23-2.73) 2.55 (2.17-2.99) 
 Model2 1.0 1.36 (1.29-1.44) 1.47 (1.33-1.63) 1.16 (0.98-1.36) 
Renal failure     
 Case 1,609 275 205 161 
 Crude 1.0 6.05 (5.30-6.91) 22.11 (18.98-25.75) 55.42 (46.76 (66.59) 
 Model1 1.0 5.50 (4.82-6.29) 17.91 (15.36-20.87) 39.53 (33,30-46.92) 
 Model2 1.0 3.75 (3.27-4.30) 8.26 (7.02-9.73) 7.89 (6.39-9.75) 
Parkinson     
 Case 1,203 41 14 8 
 Crude 1.0 1.21 (0.88-1.67) 1.78 (1.01-3.15) 3.25 (1.62-6.51) 
 Model1 1.0 1.09 (0.79-1.50) 1.27 (0.72-2.24) 1.90 (0.95-3.81) 
 Model2 1.0 1.02 (0.74-1.40) 1.16 (0.65-2.05) 1.66 (0.81-3.38) 
COPD     
 Case 18,779 595 167 53 
 Crude 1.0 1.09 (0.99-1.19) 1.47 (1.25-1.74) 1.33 (0.99-1.78) 
 Model1 1.0 1.03 (0.94-1.12) 1.22 (1.03-1.44) 0.99 (0.74-1.33) 
 Model2 1.0 1.06 (0.97-1.16) 1.31 (1.11-1.55) 1.10 (0.82-1.49) 
Pulmonary disease     
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 Case 730 33 14 7 
 Crude 1.0 1.52 (1.06-2.19) 3.36 (1.98-5.70) 4.58 (2.18-9.65) 
 Model1 1.0 1.32 (0.92-1.90) 2.46 (1.45-4.17) 2.91 (1.38-6.14) 
 Model2 1.0 1.25 (0.86-1.80) 2.16 (1.26-3.73) 2.40 (1.10-5.24) 
Liver disease     
 Case 53,624 1,871 431 141 
 Crude 1.0 1.29 (1.22-1.35) 1.27 (1.13-1.42) 1.17 (0.96-1.42) 
 Model1 1.0 1.24 (1.18-1.30) 1.18 (1.05-1.31) 1.06 (0.87-1.28) 
 Model2 1.0 1.15 (1.10-1.22) 1.04 (0.98-1.09) 0.91 (0.75-1.11) 
Model 1: unadjusted 
Model 2: adjusted for age and gender 
Model 3: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, current 
smoker, systolic blood pressure, anti-hypertensive, body mass index and dipstick proteinuria 
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J. Summary of morbidity risk by eGFR and dipstick proteinuria 
 
Low eGFR (<60 vs. ≥60 ml/min/1.73m2) was significantly associated with increased 
risk of urinary tract cancer, coronary heart disease, viral hepatitis, Parkinson’s disease 
and renal failure (Figure 7). We confirmed a similar relationship with mortality results. 
Unexpectedly, low eGFR was significantly associated with decreased risk of diabetes 
when assessing the relationship of eGFR with indicators of incident non-CVD/cancer 
(Figure A1). Low eGFR was associated with increased risk for hospitalization due to 
viral hepatitis, pneumonia and Parkinson’s disease, but not associated with risk for ≥3 for 
outpatient visits. For incidence of diabetes, the association of eGFR with hospitalization 
was not significant, but ≥3 for outpatient visits were significantly decreased. 
Proteinuria (≥1+ vs. none/trace) was significantly associated with increased risk of 
cancer of various organs (i.e., stomach, rectum, liver, ovary, urinary tract and myeloma), 
both major CVDs (i.e., coronary heart disease and stroke), pneumonia, viral hepatitis, 
diabetes, pulmonary diseases, liver disease and renal failure (Figure 8). Again, this study  
confirmed a similar relationship with mortality results. When examining the relationship 
of positive proteinuria with indicators of incident non-CVD/cancer (Figure A2). Positive 
proteinuria was associated with increased risk for hospitalization due to infectious 
diseases including viral hepatitis and pneumonia, pulmonary disease and liver disease. 
The relationship of positive proteinuria with hospitalization and ≥3 for outpatient visits 
due to diabetes and renal failure was significantly increased.   
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Figure 8. Adjusted hazard ratios of morbidity for eGFR<60 ml/min/1.73m2 (vs. ≥60) 
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Figure 9. Adjusted hazard ratios of morbidity for dipstick proteinuria (≥ + vs. none/trace) 
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K. Change in eGFR and cause specific mortality  
 
The distribution of percentage annual change in eGFR between visit 1 and visit 2 is 
shown in Figure 7. The mean (SD) of percentage annual change was 0.40% (13.39%) 
with median (inter-quartile range) of -0.70% (-10.62% to 10.32%). 
Compared with participants with stable eGFR, the unadjusted risk of CVD was 2-fold 
higher (HR 3.09, 95% CI 1.34-7.12) for those with a certain drop in 1-year (Table 16).  
When adjusted for potential confounders, CVD mortality risk was still significant [HR 
2.86 (95%CI 1.24-6.62)]. We further assessed the risk of mortality and 2, 3 and 4 years 
change in kidney measures, but not significantly associated with cause-specific mortality 
(Table A8-10). 
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Figure 10. Distribution of percentage annual change in eGFR on the basis of 1-year change 
among 56,436 participants of MSMS  
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Table 16. Hazard ratios (95%CI) for cause-specific mortality by 1 year change in eGFR 
 1 year change 
in eGFR 
  
 Stable Uncertain drop Certain drop 
 N=37,333 N=16,933 N=2,170 
Cancer mortality    
 Case 205 107 6 
 Crude 1.0 1.09 (0.87-1.38) 1.04 (0.46-2.33) 
 Model 1 1.0 1.12 (0.89-1.42) 0.95 (0.42-2.13) 
 Model 2  1.0 1.10 (0.87-1.40) 0.94 (0.42-2.13) 
CVD mortality    
 Case 70 40 6 
 Crude 1.0 1.20 (0.81-1.77) 3.09 (1.34-7.12) 
 Model 1 1.0 1.23 (0.83-1.81) 2.78 (1.20-6.41) 
 Model 2  1.0 1.24 (0.84-1.83) 2.86 (1.24-6.62) 
Non-CVD/cancer 
mortality 
   
 Case 67 69 5 
 Crude 1.0 0.98 (0.73-1.30) 1.19 (0.49-2.91) 
 Model 1 1.0 0.99 (0.74-1.32) 1.13 (0.46-2.75) 
 Model 2 1.0 0.99 (0.74-1.31) 1.11 (0.46-2.72) 
All-cause mortality    
 Case 207 216 17 
 Crude 1.0 1.07 (0.91-1.26) 1.43 (0.88-2.32) 
 Model 1 1.0 1.09 (0.93-1.29) 1.32 (0.81-2.14) 
 Model 2  1.0 1.09 (0.92-1.28) 1.32 (0.81-2.15) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, 
current smoker, systolic blood pressure, anti-hypertensive, body mass index and dipstick 
proteinuria 
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V. DISCUSSION 
 
In this large Korean cohort study, we found that low eGFR and high proteinuria 
conferred mortality risk due to CVD, cancer, and non-CVD/cancer. Low eGFR was 
mainly associated with CVD and non-CVD/cancer mortality, whereas high proteinuria 
was consistently and significantly associated with all of CVD, cancer and non-
CVD/cancer mortality outcomes. This pattern was consistent across subgroups by age 
and gender. Of note, the significant association for proteinuria was observed in trace 
proteinuria compared to negative proteinuria. In terms of finer causes of death, both 
kidney markers were commonly associated with increased risk of coronary heart disease, 
overall infectious disease, diabetes, and renal failure. In addition, high proteinuria was 
significantly associated with increased mortality due to much broader causes (i.e., stroke, 
cancer of stomach, liver, pancreas, lung, and urinary tract, myeloma, pneumonia, viral 
hepatitis, and liver disease), as compared to low eGFR (oropharyngeal cancer). We also 
explored the association between changes in kidney function over a 1 year period and 
cause-specific mortality. We found that a certain drop in the eGFR (change in CKD 
category was accompanied by a 25% decline from the baseline eGFR) was associated 
with an increased risk of CVD mortality. 
As previously reported (Matsushita et al. 2010; Hallan et al. 2007; Nagata et al. 2013; 
van der Velde et al. 2011), we confirmed the significant associations of low eGFR and 
high proteinuria with overall CVD mortality, independent of traditional risk factors such 
as blood pressure and diabetes. High proteinuria was significantly associated with death 
due to both coronary heart disease and stroke, whereas low eGFR was only significantly 
associated with coronary mortality. Our finding is consistent with a few previous studies 
reporting stronger association of stroke with high proteinuria than with low eGFR 
(Aguilar et al. 2010; Mahmoodi et al. 2014). Although exact mechanisms for the strong 
association between proteinuria and stroke independently of blood pressure are uncertain, 
this may reflect the property of proteinuria as an indicator of systemic vascular injury or 
endothelial dysfunction. Some investigators also raise inflammation and oxidative stress 
as background of proteinuria-stroke relationship (Aguilar et al. 2010; Mahmoodi et al. 
2014). 
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The association of low eGFR with cancer mortality was weak and not robust in our 
study (only significant below eGFR 45 ml/min/1.73m2 in crude or demographically 
adjusted models with our pre-specified reference of eGFR 75-89 ml/min/1.73m2 in fully 
adjusted model with eGFR 45-59 ml/min/1.73m2 as a reference). This seems to great 
extent consistent with conflicting results in previous studies (Fried et al. 2005; Iff et al. 
2014; Weng et al. 2011). A few studies reported significant associations of reduce kidney 
function (low eGFR or higher cystatin C levels) and cancer mortality but, of note, did not 
adjust for some important confounders like blood pressure, diabetes, lipids, obesity or 
proteinuria (Fried et al. 2005; Iff et al. 2014; Weng et al. 2011). One study accounted for 
these confounders and actually did not find significant associations of CKD, defined as 
reduced eGFR and/or elevated proteinuria, with cancer mortality (Di Angelantonio et al. 
2010). Unfortunately, this study did not report eGFR- or proteinuria-specific results. 
Recently, a large cohort study with more than 1 million participants has shown no 
associations of low eGFR with total cancer incidence (Lowrance et al. 2014). However, 
this study reports significant associations of low eGFR with kidney urothelial cancer 
incidences, and the association between low eGFR and kidney cancer mortality was 
borderline significant in our study. On the other hand, we observed the low eGFR was 
significantly associated with high risk of oropharyngeal and low risk of lung cancer 
mortality. A strong U-shaped relationship between eGFR and lung cancer incidence has 
been shown (Lowrance et al. 2014), with the lowest incidence at eGFR 40-59 
ml/min/1.73m2 and 1.5-2 fold higher incidence in high (90+ ml/min/1.73m2) and low 
(<30 ml/min/1.73m2) eGFR ranges. Thus, the lower risk of lung cancer mortality in 
eGFR<60 compared to ≥60 might be due to eGFR distribution in our study (few with 
eGFR<30 and a number of people with higher eGFR). Nevertheless, these results for 
specific cancer types in our study should be considered with more hypotheses and further 
investigations. For incidence of cancer, a previous study shared similar results as they 
reported that there were low eGFR incidences of urinary tract cancer in older people 
(Wong et al. 2009).  
To our knowledge, this is the first study, of its kind, to include reports on significant 
associations of proteinuria with overall and type-specific cancer mortality: although a 
previous study did report its association with incidence of cancer (Jorgensen et al. 2008).  
The associations were evident even at the level of trace or 1+ and observed for cancer of 
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stomach, liver, pancreas, lung, and urinary tract and myeloma. The significant 
associations with lung and urinary tract cancer mortality and morbidity are consistent 
with a previous study examining cancer incidence (Jorgensen et al. 2008). It was of 
interest that proteinuria was consistently associated with some gastroenterological 
cancers in our study. Although the exact mechanisms, by which proteinuria is associated 
with the risk for cancer, are unknown, several mechanisms may be involved. First, 
albuminuria may reflect prevalent cancer as patients with a large tumor burden or 
metastatic disease had higher albuminuria levels than less advanced disease (Pedersen 
and Milman 1998; Sawyer et al. 1988). This particularly relevant to myeloma releasing 
Bence-Jones proteins, light polypeptide chains of immunoglobulins, in the urine. 
However, the significant associations were consistent among those without prevalent 
cancer at baseline and when those who died in 3 years were excluded. Second, 
proteinuria may be associated with cancer growth or expansion rather than incidence. 
Indeed, endothelial dysfunction is shown to contribute to invasiveness of cancer cells 
(Franses et al. 2013). Finally endothelial dysfunction is related with inflammation 
(Stehouwer et al. 2002), inflammation have been a potential explanation for cancer 
incidence (Coussens and Werb 2002; Jorgensen et al. 2008). Considering the association 
of eGFR and proteinuria with cancer mortality and morbidity overall, low eGFR levels 
are associated with increased risk of urinary tract, whereas proteinuria is associated with 
much broader site-specific cancer risk.  
Unlike report from Western countries (Gansevoort et al. 2013; Stevens et al. 2007), 
non-CVD/cancer mortality was more common than CVD or cancer mortality in our 
participants with CVD, which is consistent with other reports from Eastern Asia (Weng 
et al. 2011). Therefore, health care providers in Eastern Asian countries should pay more 
attention to non-CVD/cancer causes of death in the CVD care. Whether this applies to 
Eastern Asian population living in Western Countries warrants further investigation.  
In this context, we found that both low eGFR and high proteinuria were strongly 
associated with non-CVD/cancer mortality, even after excluding death due to diabetes, a 
potent risk factor of CKD, and renal failure, a direct consequence of CKD. Regarding 
finer causes, both kidney measures commonly and independently associated with overall 
infectious disease mortality, which is consistent with a few previous reports (Wang et al. 
2011). In addition, proteinuria demonstrated significant associations with two specific 
62 
 
 
 
infectious diseases, pneumonia and viral hepatitis. It is known patients with CKD have 
reduced activities of immune system cell like B-cell, T-cell, monocyte and lymphocyte 
(Janus et al. 2008).  
Taking into consideration the magnitude of changes in kidney function, in addition to 
the baseline kidney function alone, might provide prognostic information. We found the 
association between 1-year decline in eGFR and CVD mortality. Other results are 
consistent with our findings. A rapid decline of eGFR was at significantly greater risk for 
cardiovascular disease (Al-Aly et al. 2010; Matsushita et al. 2009; Perkins et al. 2011; 
Rifkin et al. 2008; Turin et al. 2014).  
Taken altogether, our findings suggest that person with CKD warrants 
multidisciplinary care for side range of disease. More specifically, in addition to CVD, 
special attention would be needed for infectious disease prevention and management 
such as vaccination programs (Janus et al. 2008; Kidney Disease: Improving Global 
Outcomes 2013). Although our results need be confirmed in other settings, individuals 
with proteinuria would deserve further consideration for cancer risk. Although further 
investigations are clearly needed regarding how to implement cancer screening in the 
context of CKD, the assessment of proteinuria is already recommended in some clinical 
populations such as diabetes and hypertension and screening programs for some cancers 
such as lung cancer (aged 55-80 years with some smoking history) (Davis and Cifu 2014) 
and stomach cancer (aged ≥40 years) (Leung et al. 2008) is well developed in several 
countries/regions. Thus, when proteinuria is detected in some clinical scenarios, it seems 
reasonable to encourage persons with proteinuria to adhere to those cancer screening 
programs.  
A trace of proteinuria is usually regarded as a negative result and the clinical 
significance is likely to be ignored in the general population. Previous study suggested 
that trace of proteinuria using a dipstick test could be a useful indicator for 
microalbuminuria (Konta T et al. 2007). The association of trace of proteinuria and 
cause-specific mortality was evident in our study; therefore, further investigations are 
needed. 
This study has a few limitations. First, our cohort may not necessarily represent 
general population in the Korea, since the study participants were in routine health 
assessments at private health promotion centers, so they have higher socioeconomic 
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status and relatively small number of older individuals (Jee et al. 2013). Second, our 
cohort has a small number of participants with severely reduced eGFR 
(<30ml/min/1.73m2). Third, cystatin C was not available. Cystatin C is known a stronger 
predictor of mortality and CVD outcomes than serum creatinine when incorporated in 
eGFR equations (Herget-Rosenthal et al. 2000; Shlipak et al. 2005). Thus, investigations 
with cystatins C for cancer and non-CVD/cancer mortality are warranted. Forth, we used 
semi-quantitative urinary dipstick test as a measure of kidney damage. As it does not 
account for urine concentration, it is likely that there were some misclassifications of 
proteinuria. However, this kind of misclassification usually biases the association toward 
null. Finally, the outcome definition was based on ICD-10 code from death certificates. 
There have been debates about the accuracy of this approach (Chun and Lee 2000), 
although this approach is widely used in literature (Harteloh, de Bruin and Kardaun 
2010; Lu, Lee and Chou 2000; Winkler, Ott and Becher 2010) and the accuracy of cancer 
as a cause of death was reported to be high (Lee et al. 2000; Song and Sung 2001).  
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VI. CONCLUSIONS 
 
  Low eGFR was particularly associated with mortality due to CVD and non-
CVD/cancer. In contrast, high proteinuria was consistently and robustly associated with 
deaths due to CVD, cancer, and non-CVD/cancer. Our study provides further evidence 
that persons with CKD are at high risk for not only CVD but also other causes of deaths 
such as cancer (particularly when proteinuria is present) and infectious disease. 
Therefore, multidisciplinary prevention and management strategies need to be 
encouraged. 
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APPENDIX 
 
Table A1. Hazard ratios (95%CI)* for cause-specific mortality by eGFR using competing risk model 
 eGFR, ml/min/1.73m2 
 ≥105 90-104 75-89 60-74 45-59 <45 
 N=87,468 N=139,902 N=105,839 N=31,081 N=3,136 N=338 
Cancer mortality       
 Case 339 1,287 1,507 741 128 26 
 Crude 0.27 (0.24-0.30) 0.65 (0.60-0.70) 1.0 1.64 (1.51-1.80) 2.82 (2.35-3.38) 4.51 (3.18-6.39) 
 Model 1 1.24 (1.09-1.42) 1.09 (1.01-1.18) 1.0 0.91 (0.83-1.00) 0.72 (0.59-0.86) 1.17 (0.81-1.71) 
Model 2 (impute) 1.13 (1.00-1.29) 1.05 (0.97-1.13) 1.0 0.95 (0.87-1.04) 0.74 (0.61-0.89) 0.98 (0.66-1.48) 
CVD mortality       
 Case 103 447 570 335 118 23 
 Crude 0.22 (0.18-0.27) 0.60 (0.53-0.68) 1.0 1.96 (1.71-2.24) 6.88 (5.64-8.39) 12.74 (9.02-17.99) 
 Model 1 1.14 (0.91-1.44) 1.05 (0.92-1.19) 1.0 1.03 (0.90-1.19) 1.59 (1.29-1.96) 2.93 (2.02-4.26) 
Model 2 (impute) 1.13 (0.90-1.42) 1.04 (0.91-1.18) 1.0 0.99 (0.86-1.13) 1.31 (1.06-1.63) 1.69 (1.15-2.50) 
Non-CVD/cancer mortality       
 Case 396 1,019 992 512 153 40 
 Crude 0.48 (0.42-0.54) 0.78 (0.71-0.85) 1.0 1.72 (1.55-1.91) 5.13 (4.33-6.08) 17.51 (13.92-22.03) 
 Model 1 1.96 (1.73-2.24) 1.26 (1.15-1.38) 1.0 0.99 (0.88-1.10) 1.44 (1.21-1.71) 5.00 (3.84-6.51) 
Model 2 (impute) 1.69 (1.49-1.93) 1.19 (1.09-1.31) 1.0 1.02 (0.92-1.14) 1.38 (1.15-1.65) 2.85 (2.14-3.80) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, current smoker, systolic blood pressure, anti-hypertensive, 
body mass index and dipstick proteinuria 
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Table A2. Hazard ratios (95%CI)* for cause-specific mortality by dipstick proteinuria using 
competing risk model 
 Dipstick proteinuria 
 None/trace 1+ 2+ ≥3+ 
 N=354,433 N=10,090 N=2,545 N=864 
Cancer mortality     
 Case 3,725 219 59 32 
 Crude 1.0 1.83 (1.60-2.10) 2.13 (1.65-2.76) 3.05 (2.15-4.32) 
 Model 1 1,0 1.43 (1.24-1.64) 1.39 (1.07-1.81) 1.63 (1.14-2.33) 
 Model 2 (impute) 1.0 1.39 (1.20-1.69) 1.41 (1.08-1.84) 1.70 (1.17-2.46) 
CVD mortality     
 Case 1,395 135 42 36 
 Crude 1.0 3.03 (2.54-3.62) 4.05 (2.98-5.51) 9.27 (6.64-12.94) 
 Model 1 1.0 2.30 (1.92-2.75) 2.47 (1.81-3.38) 4.67 (3.31-6.60) 
 Model 2 (impute) 1.0 1.79 (1.49-2.16) 1.59 (1.14-2.22) 2.32 (1.56-3.45) 
Non-CVD/cancer 
mortality 
    
 Case 2,750 225 103 74 
 Crude 1.0 2.54 (2.21-2.91) 5.07 (4.17-6.18) 9.67 (7.67-12.19) 
 Model 1 1.0 2.06 (1.80-2.37) 3.54 (2.90-4.31) 5.73 (4.53-7.27) 
 Model 2 (impute) 1.0 1.69 (1.46-1.95) 2.61 (2.11-3.23) 3.40 (2.59-4.48) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, 
current smoker, systolic blood pressure, anti-hypertensive, body mass index and eGFR 
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Table A3. Hazard ratios (95%CI) for site-specific cancer incidence by eGFR 
 eGFR, ml/min/1.73m2 
 ≥105 90-104 75-89 60-74 45-59 <45 
 N=41,032 N=91,204 N=74,913 N=23,646 N=2,116 N=308 
Small intestine       
 Case 8 18 29 8 2 0 
 Crude 0.51 (0.23-1.11) 0.52 (0.29-0.93) 1.0 0.86 (0.39-1.89) 2.47 (0.59-10.34) - 
 Model1 1.51 (0.64-3.55) 0.73 (0.40-1.32) 1.0 0.54 (0.25-1.20) 0.94 (0.22-4.02) - 
 Model2 1.43 (0.61-3.37) 0.75 (0.42-1.34) 1.0 0.51 (0.23-1.13) 1.18 (0.34-4.05) - 
Larynx       
 Case 8 30 34 17 2 1 
 Crude 0.43 (0.20-0.92) 0.73 (0.45-1.19) 1.0 1.57 (0.88-2.81) 2.09 (0.50-8.70) 8.04 (1.10-58.72) 
 Model1 1.95 (0.85-4.48) 1.18 (0.71-1.94) 1.0 0.91 (0.50-1.64) 0693 (0.16-2.90) 3.03 (0.41-22.38) 
 Model2 1.94 (0.84-4.44) 1.22 (0.74-1.98) 1.0 0.93 (0.52-1.66) 1.01 (0.30-3.39) 3.70 (0.48-28.46) 
Bone and articular cartilage       
 Case 4 26 34 13 1 0 
 Crude 0.21 (0.08-0.60) 0.63 (0.38-1.05) 1.0 1.20 (0.64-2.28) 1.06 (0.14-7.73) - 
 Model1 0.42 (0.14-1.22) 0.79 (0.47-1.33) 1.0 0.87 (0.45-1.67) 0.53 (0.07-3.96) - 
 Model2 0.42 (0.14-1.22) 0.86 (0.52-1.43) 1.0 0.84 (0.44-1.62) 0.47 (0.06-3.54) - 
Skin       
 Case 13 54 58 29 2 1 
 Crude 0.41 (0.22-0.75) 0.77 (0.53-1.12) 1.0 1.57 (1.00-2.45) 1.24 (0.30-5.07) 4.86 (0.67-35.00) 
 Model1 0.92 (0.49-1.74) 1.01 (0.69-1.46) 1.0 1.03 (0.65-1.62) 0.51 (0.12-2.09) 2.34 (0.32-16.99) 
 Model2 0.92 (0.49-1.71) 0.96 (0.66-1.39) 1.0 0.97 (0.62-1.52) 0.42 (0.10-1.74) 1.58 (0.20-12.46) 
Soft tissue       
 Case 18 56 51 25 0 0 
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 Crude 0.64 (0.37-1.09) 0.90 (0.62-1.32) 1.0 1.55 (0.96-2.50) - - 
 Model1 1.02 (0.58-1.81) 1.06 (0.72-1.56) 1.0 1.17 (0.72-1.90) - - 
 Model2 1.06 (0.60-1.89) 1.08 (0.74-1.59) 1.0 1.14 (0.70-1.86) - - 
Cervix*       
 Case 28 70 52 17 2 0 
 Crude 0.77 (0.48-1.21) 1.05 (0.73-1.50) 1.0 0.84 (0.48-1.45) 0.80 (0.20-3.29) - 
 Model1 1.11 (0.68-1.83) 1.19 (0.83-1.72) 1.0 0.69 (0.40-1.20) 0.56 (0.14-2.33) - 
 Model2 1.12 (0.68-1.84) 1.20 (0.83-1.72) 1.0 0.68 (0.39-1.18) 0.50 (0.12-2.09) - 
Unspecified parts of uterus*       
 Case 29 55 30 15 2 0 
 Crude 1.36 (0.82-2.27) 1.42 (0.91-2.22) 1.0 1.27 (0.68-2.36) 1.38 (0.33-5.76) - 
 Model1 2.05 (1.17-3.58) 1.64 (1.05-2.58) 1.0 1.03 (0.55-1.93) 0.94 (0.22-3.96) - 
 Model2 2.12 (1.21-3.70) 1.65 (1.05-2.59) 1.0 1.01 (0.54-1.89) 0.78 (0.18-3.35) - 
Prostate†       
 Case 34 268 323 196 27 3 
 Crude 0.22 (0.15-0.31) 0.70 (0.60-0.83) 1.0 2.14 (1.79-2.55) 4.50 (3.04-6.66) 3.23 (1.04-10.07) 
 Model1 0.90 (0.62-1.29) 1.10 (0.94-1.30) 1.0 1.11 (0.93-1.33) 1.01 (0.68-1.51) 1.02 (0.33-3.18) 
 Model2 0.96 (0.66-1.38) 1.15 (0.97-1.35) 1.0 1.07 (0.89-1.28) 0.95 (0.64-1.42) 0.98 (0.31-3.13) 
Kidney       
 Case 46 127 143 52 10 9 
 Crude 0.58 (0.42-0.81) 0.73 (0.58-0.93) 1.0 1.15 (0.83-1.57) 2.52 (1.33-4.78) 17.39 (8.87-34.10) 
 Model1 0.93 (0.66-1.33) 0.86 (0.67-1.09) 1.0 0.96 (0.70-1.33) 1.78 (0.92-3.42) 13.19 (6.67-26.09) 
 Model2 0.90 (0.64-1.28) 0.86 (0.68-1.09) 1.0 0.94 (0.69-1.28) 1.50 (0.80-2.82) 10.45 (5.32-20.53) 
Ureter       
 Case 3 22 19 14 4 2 
 Crude 0.28 (0.08-0.96) 0.95 (0.52-1.76) 1.0 2.32 (1.16-4.63) 7.54 (2.57-22.18) 29.23 (6.81-125.51) 
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 Model1 1.29 (0.36-4.64) 1.53 (0.82-2.85) 1.0 1.28 (0.64-2.59) 2.24 (0.74-6.76) 10.14 (2.32-44.44) 
 Model2 1.05 (0.30-3.74) 1.48 (0.82-2.65) 1.0 1.27 (0.66-2.44) 1.81 (0.60-5.46) 9.92 (2.24-43.97) 
Bladder       
 Case 18 110 136 94 14 2 
 Crude 0.24 (0.15-0.39) 0.66 (0.52-0.85) 1.0 2.19 (1.68-2.84) 3.74 (2.16-6.48) 4.10 (1.01-16.54) 
 Model1 0.74 (0.44-1.23) 0.95 (0.74-1.23) 1.0 1.39 (1.06-1.82) 1.48 (0.84-2.59) 1.88 (0.46-7.64) 
 Model2 0.70 (0.42-1.17) 1.03 (0.81-1.31) 1.0 1.35 (1.05-1.75) 1.28 (0.74-2.21) 1.20 (0.29-5.02) 
Thyroid gland       
 Case 572 1,142 880 267 25 3 
 Crude 1.19 (1.07-1.32) 1.07 (0.98-1.17) 1.0 0.95 (0.83-1.09) 1.02 (0.69-1.52) 0.96 (0.31-2.97) 
 Model1 0.94 (0.84-1.05) 1.00 (0.91-1.09) 1.0 0.95 (0.82-1.09) 0.94 (0.63-1.41) 0.91 (0.29-2.82) 
 Model2 0.92 (0.83-1.03) 0.99 (0.91-1.08) 1.0 0.92 (0.80-1.05) 0.94 (0.65-1.36) 0.73 (0.23-2.31) 
Other endocrine gland       
 Case 10 15 17 10 0 0 
 Crude 1.08 (0.50-2.37) 0.73 (0.36-1.46) 1.0 1.86 (0.85-4.05) - - 
 Model1 2.04 (0.86-4.82) 0.91 (0.45-1.84) 1.0 1.28 (0.58-2.84) - - 
 Model2 2.12 (0.89-5.03) 0.93 (0.46-1.87) 1.0 1.24 (0.56-2.77) - - 
Unspecified sites       
 Case 393 1,272 1,325 594 70 15 
 Crude 0.54 (0.48-0.61) 0.79 (0.73-0.86) 1.0 1.41 (1.28-1.56) 1.90 (1.49-2.42) 3.15 (1.89-5.24) 
 Model1 1.22 (1.08-1.38) 1.04 (0.96-1.12) 1.0 0.94 (0.85-1.03) 0.79 (0.62-1.01) 1.54 (0.93-2.57) 
 Model2 1.17 (1.04-1.32) 1.02 (0.94-1.10) 1.0 0.96 (0.87-1.05) 0.82 (0.64-1.05) 1.43 (0.85-2.42) 
* Only Women; † Only men 
Model 1: unadjusted 
Model 2: adjusted for age and gender 
Model 3: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, current smoker, systolic blood pressure, anti-hypertensive, body mass index and dipstick proteinuria 
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Table A4. Hazard ratios (95%CI) for site-specific cancer incidence by dipstick proteinuria 
 Dipstick proteinuria 
 None/trace 1+ 2+ ≥3+ 
 N=224,973 N=6,331 N=1,421 N=494 
Small intestine     
 Case 59 4 1 1 
 Crude 1.0 2.37 (0.86-6.52) 2.83 (0.39-20.43) 7.73 (1.07-55.83) 
 Model1 1.0 2.03 (0.74-5.59) 2.06 (0.28-14.91) 4.90 (0.67-35.51) 
 Model2 1.0 1.78 (0.64-4.98) 1.82 (0.25-13.38) 4.69 (0.62-35.38) 
Larynx     
 Case 87 4 1 0 
 Crude 1.0 1.62 (0.59-4.42) 1.89 (0.26-13.57) - 
 Model1 1.0 1.19 (0.44-3.25) 1.12 (0.16-8.08) - 
 Model2 1.0 1.03 (0.37-2.83) 0.80 (0.11-6.07) - 
Bone and articular cartilage     
 Case 73 4 1 0 
 Crude 1.0 1.91 (0.70-5.24) 2.28 (0.32-16.39) - 
 Model1 1.0 1.72 (0.63-4.72) 1.80 (0.25-12.95) - 
 Model2 1.0 1.53 (0.55-4.24) 1.58 (0.22-11.52) - 
Skin     
 Case 148 7 1 1 
 Crude 1.0 1.66 (0.78-3.55) 1.13 (0.16-8.07) 3.09 (0.43-22.11) 
 Model1 1.0 1.55 (0.72-3.31) 0.90 (0.13-6.46) 2.21 (0.31-15.85) 
 Model2 1.0 1.60 (0.78-3.29) 0.77 (0.11-5.60) 1.77 (0.23-13.73) 
Soft tissue     
 Case 143 4 3 0 
 Crude 1.0 0.99 (0.37-2.68) 3.46 (1.10-10.87) - 
 Model1 1.0 0.96 (0.36-2.60) 3.06 (0.97-9.61) - 
 Model2 1.0 1.01 (0.37-2.74) 3.45 (1.09-10.96) - 
Cervix*     
 Case 161 6 1 1 
 Crude 1.0 1.70 (0.75-3.84) 1.19 (0.17-8.53) 3.09 (0.43-22.06) 
 Model1 1.0 1.69 (0.72-3.82) 1.13 (0.16-8.04) 2.86 (0.40-20.42) 
 Model2 1.0 1.64 (0.72-3.71) 1.17 (0.16-8.45) 3.30 (0.45-24.10) 
Unspecified parts of uterus*     
 Case 124 2 4 1 
 Crude 1.0 0.74 (0.18-2.98) 6.39 (2.36-17.29) 4.00 (0.56-28.66) 
 Model1 1.0 0.73 (0.18-2.97) 6.08 (2.24-16.46) 3.78 (0.53-27.05) 
 Model2 1.0 0.67 (0.16-2.71) 5.42 (1.97-14.92) 3.54 (0.48-26.09) 
Prostate†     
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 Case 799 39 8 5 
 Crude 1.0 1.54 (1.11-2.12) 1.55 (0.77-3.10) 2.72 (1.13-6.55) 
 Model1 1.0 1.24 (0.90-1.71) 0.95 (0.48-1.92) 1.28 (0.53-3.09) 
 Model2 1.0 1.28 (0.92-1.77) 0.98 (0.48-1.99) 1.35 (0.55-3.31) 
Kidney     
 Case 358 16 10 3 
 Crude 1.0 1.58 (0.96-2.61) 4.64 (2.48-8.70) 3.84 (1.23-11.98) 
 Model1 1.0 1.41 (0.85-2.33) 3.85 (2.05-7.23) 3.00 (0.96-9.37) 
 Model2 1.0 1.25 (0.76-2.04) 2.80 (1.51-5.18) 1.42 (0.48-4.15) 
Ureter     
 Case 59 5 0 0 
 Crude 1.0 2.96 (1.19-7.39) - - 
 Model1 1.0 2.31 (0.93-5.78) - - 
 Model2 1.0 2.30 (0.97-5.41) - - 
Bladder     
 Case 345 19 7 3 
 Crude 1.0 1.94 (1.22-3.08) 3.38 (1.60-7.15) 3.97 (1.28-12.38) 
 Model1 1.0 1.56 (0.98-2.47) 2.24 (1.06-4.74) 2.21 (0.71-6.90) 
 Model2 1.0 1.40 (0.89-2.21) 2.39 (1.21-4.69) 1.79 (0.56-5.73) 
Thyroid gland     
 Case 2,810 58 13 8 
 Crude 1.0 0.73 (0.56-0.94) 0.77 (0.45-1.33) 1.32 (0.66-2.65) 
 Model1 1.0 0.81 (0.62-1.05) 0.85 (0.49-1.46) 1.42 (0.71-2.83) 
 Model2 1.0 0.80 (0.62-1.03) 1.01 (0.62-1.63) 1.32 (0.65-2.66) 
Other endocrine gland     
 Case 50 2 0 0 
 Crude 1.0 1.41 (0.34-5.81) - - 
 Model1 1.0 1.37 (0.33-5.63) - - 
 Model2 1.0 1.35 (0.33-5.63) - - 
Unspecified sites     
 Case 3,473 150 32 14 
 Crude 1.0 1.53 (1.30-1.80) 1.53 (1.08-2.16) 1.87 (1.11-3.16) 
 Model1 1.0 1.40 (1.19-1.65) 1.22 (0.86-1.73) 1.32 (0.78-2.23) 
 Model2 1.0 1.39 (1.18-1.64) 1.20 (0.85-1.71) 1.29 (0.75-2.21) 
 * Only Women 
† Only men 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, current 
smoker, systolic blood pressure, anti-hypertensive, body mass index and eGFR 
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Table A5. Hazard ratios (95%CI) for indicators of incident non-CVD/cancer by eGFR 
 eGFR, ml/min/1.73m2 
 ≥105 90-104 75-89 60-74 45-59 <45 
 N=41,032 N=91,204 N=74,913 N=23,646 N=2,116 N=308 
Infectious disease       
 Inpatients       
  Crude 0.87 (0.84-0.90) 0.96 (0.94-0.99) 1.0 1.21 (1.17-1.25) 1.76 (1.62-1.92) 3.17 (2.65-3.80) 
  Model1 1.21 (1.17-1.25) 1.08 (1.06-1.11) 1.0 0.98 (0.95-1.02) 1.11 (1.02-1.21) 2.17 (1.81-2.59) 
  Model2 1.20 (1.16-1.24) 1.08 (1.05-1.11) 1.0 0.98 (0.95-1.02) 1.10 (1.01-1.20) 1.87 (1.55-2.26) 
 Outpatients       
  Crude 0.97 (0.95-0.98) 0.99 (0.97-1.00) 1.0 1.01 (0.98-1.03) 1.02 (0.94-1.09) 0.89 (0.74-1.08) 
  Model1 0.98 (0.96-1.00) 0.99 (0.98-1.01) 1.0 0.99 (0.96-1.01) 0.96 (0.89-1.03) 0.87 (0.72-1.05) 
  Model2 0.98 (0.96-1.00) 0.99 (0.98-1.01) 1.0 0.99 (0.96-1.01) 0.96 (0.89-1.04) 0.90 (0.74-1.10) 
Viral hepatitis       
 Inpatients       
  Crude 1.10 (0.98-1.24) 1.02 (0.92-1.12) 1.0 0.98 (0.85-1.13) 1.39 (0.96-2.00) 3.19 (1.65-6.15) 
  Model1 1.23 (1.09-1.39) 1.05 (0.96-1.16) 1.0 0.95 (0.82-1.10) 1.33 (0.92-1.92) 3.07 (1.59-5.94) 
  Model2 1.21 (1.07-1.36) 1.04 (0.95-1.15) 1.0 0.96 (0.83-1.11) 1.32 (0.91-1.92) 2.48 (1.24-4.95) 
 Outpatients       
  Crude 0.95 (0.89-1.00) 0.97 (0.93-1.02) 1.0 1.06 (0.99-1.13) 1.07 (0.87-1.30) 1.45 (0.90-2.34) 
  Model1 1.03 (0.97-1.10) 1.00 (0.96-1.05) 1.0 1.02 (0.95-1.09) 0.98 (0.80-1.20) 1.36 (0.85-2.20) 
  Model2 1.04 (0.97-1.10) 1.00 (0.96-1.05) 1.0 1.01 (0.94-1.09) 0.97 (0.79-1.19) 1.34 (0.82-2.18) 
Pneumonia       
 Inpatients       
  Crude 0.54 (0.49-0.60) 0.84 (0.79-0.90) 1.0 1.57 (1.45-1.71) 3.04 (2.56-3.60) 6.59 (4.82-9.02) 
  Model1 1.40 (1.26-1.55) 1.14 (1.07-1.22) 1.0 0.99 (0.91-1.07) 1.14 (0.96-1.35) 2.92 (2.13-4.00) 
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  Model2 1.29 (1.16-1.44) 1.11 (1.03-1.18) 1.0 1.01 (0.93-1.10) 1.16 (0.98-1.38) 2.04 (1.47-2.85) 
 Outpatients       
  Crude 0.80 (0.76-0.84) 0.93 (0.90-0.96) 1.0 1.27 (1.21-1.34) 1.56 (1.37-1.78) 1.43 (0.99-2.08) 
  Model1 1.06 (1.01-1.12) 1.03 (1.00-1.07) 1.0 1.03 (0.98-1.08) 0.96 (0.84-1.10) 1.00 (0.69-1.45) 
  Model2 1.05 (1.00-1.10) 1.03 (0.99-1.07) 1.0 1.04 (0.99-1.09) 0.98 (0.86-1.12) 1.02 (0.70-1.48) 
Diabetes       
 Inpatients       
  Crude 0.64 (0.60-0.69) 0.89 (0.85-0.93) 1.0 1.46 (1.37-1.55) 2.44 (2.12-2.81) 6.16(4.78-7.94) 
  Model1 1.48 (1.37-1.59) 1.17 (1.12-1.23) 1.0 0.96 (0.90-1.02) 1.01 (0.87-1.17) 2.94 (2.28-3.79) 
  Model2 1.45 (1.34-1.56) 1.17 (1.11-1.23) 1.0 0.93 (0.87-0.99) 0.91 (0.79-1.05) 1.62 (1.24-2.11) 
 Outpatients       
  Crude 0.61 (0.59-0.63) 0.84 (0.82-0.86) 1.0 1.35 (1.30-1.40) 1.83 (1.67-2.01) 2.45 (1.96-3.06) 
  Model1 1.08 (1.04-1.12) 1.02 (1.00-1.05) 1.0 1.00 (0.96-1.04) 0.95 (0.87-1.04) 1.44 (1.16-1.80) 
  Model2 1.19 (1.14-1.24) 1.08 (1.05-1.11) 1.0 0.94 (0.91-0.98) 0.77 (0.70-0.85) 0.77 (0.61-0.96) 
Renal failure       
 Inpatients       
  Crude 0.51 (0.39-0.66) 0.78 (0.66-0.93) 1.0 2.63 (2.19-3.15) 13.82 (10.93-17.48) 243.44 (198.67-298.31) 
  Model1 0.97 (0.74-1.27) 0.97 (0.81-1.16) 1.0 1.94 (1.61-2.33) 7.23 (5.65-9.25) 135.20 (108.85-167.92) 
  Model2 0.92 (0.70-1.21) 0.96 (0.80-1.14) 1.0 1.74 (1.45-2.10) 4.68 (3.64-6.02) 31.77 (24.63-40.97) 
 Outpatients       
  Crude 0.41 (0.33-0.51) 0.69 (0.60-0.79) 1.0 3.13 (2.74-3.57) 16.57 (13.99-19.63) 213.30 (178.39-255.05) 
  Model1 0.62 (0.50-0.77) 0.79 (0.69-0.91) 1.0 2.66 (2.32-3.04) 11.93 (9.96-14.29) 159.77 (132.27-193.00) 
  Model2 0.62 (0.49-0.77) 0.80 (0.69-0.91) 1.0 2.37 (2.07-2.71) 7.65 (6.36-9.20) 39.31 (31.65-48.82) 
Parkinson       
 Inpatients       
  Crude 0.16 (0.09-0.28) 0.62 (0.48-0.79) 1.0 2.36 (1.84-3.01) 9.80 (6.91-13.90) 3.80 (0.94-15.32) 
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  Model1 0.95 (0.53-1.72) 1.05 (0.82-1.35) 1.0 1.14 (0.89-1.46) 2.12 (1.48-3.04) 0.96 (0.24-3.90) 
  Model2 0.94 (0.52-1.71) 1.05 (0.81-1.34) 1.0 1.14 (0.88-1.46) 2.12 (1.48-3.05) 0.93 (0.22-3.85) 
 Outpatients       
  Crude 0.22 (0.16-0.29) 0.63 (0.55-0.73) 1.0 1.96 (1.67-2.28) 5.47 (4.19-7.14) 2.71 (1.01-7.25) 
  Model1 0.91 (0.67-1.24) 0.99 (0.85-1.14) 1.0 1.03 (0.88-1.21) 1.44 (1.10-1.89) 0.84 (0.31-2.25) 
  Model2 0.91 (0.67-1.24) 0.99 (0.85-1.14) 1.0 1.03 (0.88-1.20) 1.41 (1.07-1.86) 0.71 (0.26-1.93) 
COPD       
 Inpatients       
  Crude 0.39 (0.32-0.47) 0.79 (0.71-0.89) 1.0 1.65 (1.44-1.89) 2.70 (1.99-3.65) 0.46 (0.06-3.24) 
  Model1 1.80 (1.47-2.21) 1.27 (1.13-1.43) 1.0 0.88 (0.77-1.02) 0.74 (0.55-1.01) 0.14 (0.02-1.03) 
  Model2 1.55 (1.27-1.91) 1.19 (1.06-1.34) 1.0 0.96 (0.84-1.11) 0.88 (0.65-1.20) 0.14 (0.02-1.01) 
 Outpatients       
  Crude 0.55 (0.52-0.58) 0.82 (0.79-0.85) 1.0 1.37 (1.31-1.44) 1.97 (1.75-2.21) 1.76 (1.27-2.46) 
  Model1 1.06 (1.00-1.12) 1.03 (0.99-1.07) 1.0 0.94 (0.90-0.99) 0.88 (0.78-0.99) 0.94 (0.67-1.31) 
  Model2 1.04 (0.99-1.11) 1.02 (0.98-1.06) 1.0 0.96 (0.91-1.00) 0.89 (0.79-1.01) 0.90 (0.64-1.26) 
Pulmonary disease       
 Inpatients       
  Crude 0.54 (0.39-0.75) 0.67 (0.53-0.84) 1.0 2.04 (1.59-2.62) 2.82 (1.57-5.07) 10.80 (4.78-24.41) 
  Model1 1.89 (1.32-2.70) 0.99 (0.78-1.26) 1.0 1.19 (0.92-1.54) 0.92 (0.51-1.67) 4.16 (1.83-9.46) 
  Model2 1.80 (1.26-2.58) 0.97 (0.77-1.23) 1.0 1.18 (0.92-1.53) 0.87 (0.48-1.57) 2.36 (0.98-5.68) 
 Outpatients       
  Crude 0.45 (0.33-0.62) 0.66 (0.53-0.82) 1.0 1.46 (1.13-1.89) 1.76 (0.90-3.43) 4.56 (1.46-14.26) 
  Model1 1.17 (0.83-1.65) 0.89 (0.72-1.11) 1.0 0.96 (0.74-1.25) 0.73 (0.37-1.44) 2.22 (0.71-6.98) 
  Model2 1.14 (0.81-1.61) 0.88 (0.70-1.09) 1.0 0.99 (0.76-1.28) 0.78 (0.40-1.54) 2.11 (0.64-6.93) 
Liver disease       
 Inpatients       
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  Crude 0.89 (0.83-0.96) 1.04 (0.98-1.10) 1.0 1.06 (0.98-1.15) 1.23 (0.97-1.55) 2.73 (1.78-4.20) 
  Model1 1.31 (1.21-1.42) 1.19 (1.12-1.26) 1.0 0.88 (0.81-0.96) 0.83 (0.66-1.05) 2.02 (1.31-3.11) 
  Model2 1.30 (1.20-1.40) 1.18 (1.12-1.25) 1.0 0.88 (0.81-0.96) 0.82 (0.65-1.03) 1.65 (1.06-2.57) 
 Outpatients       
  Crude 0.85 (0.83-0.88) 0.96 (0.94-0.98) 1.0 1.11 (1.08-1.15) 1.21 (1.10-1.33) 1.02 (0.78-1.35) 
  Model1 1.07 (1.04-1.10) 1.04 (1.02-1.07) 1.0 0.99 (0.96-1.03) 0.95 (0.87-1.04) 0.85 (0.64-1.11) 
  Model2 1.11 (1.08-1.15) 1.06 (1.04-1.09) 1.0 0.96 (0.93-1.00) 0.88 (0.80-0.96) 0.77 (0.58-1.02) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, current smoker, systolic blood pressure, anti-hypertensive, body mass index and 
dipstick proteinuria 
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Table A6. Hazard ratios (95%CI) for indicators of incident non-CVD/cancer by dipstick 
proteinuria 
 Dipstick proteinuria 
 None/trace 1+ 2+ ≥3+ 
 N=224,973 N=6,331 N=1,421 N=494 
Infectious disease     
 Inpatients     
  Crude 1.0 1.21 (1.14-1.28) 1.38 (1.23-1.55) 2.10 (1.78-2.48) 
  Model1 1.0 1.18 (1.11-1.25) 1.28 (1.14-1.43) 1.82 (1.54-2.15) 
  Model2 1.0 1.16 (1.10-1.23) 1.22 (1.09-1.38) 1.67 (1.41-1.98) 
 Outpatients     
  Crude 1.0 1.00 (0.96-1.03) 0.93 (0.85-1.01) 0.93 (0.81-1.06) 
  Model1 1.0 1.00 (0.96-1.04) 0.92 (0.85-1.00) 0.92 (0.80-1.05) 
  Model2 1.0 1.00 (0.97-1.04) 0.93 (0.85-1.01) 0.95 (0.83-1.09) 
Viral hepatitis     
 Inpatients     
  Crude 1.0 1.35 (1.10-1.67) 1.46 (0.95-2.25) 2.19 (1.21-3.95) 
  Model1 1.0 1.31 (1.06-1.62) 1.41 (0.92-2.17) 2.11 (1.17-3.82) 
  Model2 1.0 1.30 (1.05-1.60) 1.35 (0.88-2.09) 1.95 (1.05-3.62) 
 Outpatients     
  Crude 1.0 1.15 (1.03-1.29) 1.23 (0.97-1.55) 1.03 (0.67-1.58) 
  Model1 1.0 1.13 (1.01-1.26) 1.19 (0.95-1.50) 0.99 (0.64-1.52) 
  Model2 1.0 1.11 (0.99-1.25) 1.15 (0.91-1.45) 0.95 (0.61-1.47) 
Pneumonia     
 Inpatients     
  Crude 1.0 1.56 (1.36-1.79) 2.37 (1.86-3.01) 4.43 (3.30-5.94) 
  Model1 1.0 1.43 (1.25-1.65) 1.84 (1.44-2.34) 3.05 (2.27-4.09) 
  Model2 1.0 1.39 (1.21-1.60) 1.72 (1.34-2.20) 2.60 (1.91-3.54) 
 Outpatients     
  Crude 1.0 1.02 (0.93-1.12) 1.07 (0.88-1.30) 0.98 (0.70-1.37) 
  Model1 1.0 1.02 (0.93-1.12) 1.00 (0.82-1.21) 0.86 (0.62-1.21) 
  Model2 1.0 1.04 (0.95-1.15) 1.04 (0.86-1.27) 0.91 (0.65-1.28) 
Diabetes     
 Inpatients     
  Crude 1.0 2.60 (2.39-2.83) 4.09 (3.55-4.73) 6.38 (5.23-7.78) 
  Model1 1.0 2.43 (2.24-2.64) 3.36 (2.91-3.87) 4.83 (3.96-5.89) 
  Model2 1.0 1.38 (1.27-1.51) 1.54 (1.33-1.78) 2.14 (1.74-2.63) 
 Outpatients     
  Crude 1.0 2.01 (1.90-2.12) 2.84 (2.57-3.14) 3.15 (2.68-3.71) 
  Model1 1.0 1.95 (1.85-2.06) 2.53 (2.29-2.80) 2.58 (2.20-3.04) 
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  Model2 1.0 1.38 (1.31-1.46) 1.48 (1.34-1.64) 1.15 (0.97-1.36) 
Renal failure     
 Inpatients     
  Crude 1.0 8.00 (6.70-9.55) 25.17 (20.34-31.15) 92.11 (75.56-112.28) 
  Model1 1.0 7.28 (6.10-8.70) 19.71 (15.91-24.42) 62.60 (51.21-76.53) 
  Model2 1.0 4.68 (3.90-5.63) 6.92 (5.46-8.77) 10.87 (8.36-14.12) 
 Outpatients     
  Crude 1.0 7.05 (6.12-8.13) 27.62 (23.59-32.35) 70.47 (59.26-83.80) 
  Model1 1.0 6.44 (5.59-7.43) 22.76 (19.42-26.67) 52.13 (43.77-62.10) 
  Model2 1.0 4.29 (3.71-4.96) 9.96 (8.40-11.80) 9.13 (7.32-11.39) 
Parkinson     
 Inpatients     
  Crude 1.0 1.03 (0.58-1.84) 1.24 (0.40-3.86) 3.35 (1.08-10.42) 
  Model1 1.0 0.91 (0.51-1.63) 0.85 (0.27-2.64) 1.82 (0.58-5.68) 
  Model2 1.0 0.78 (0.43-1.38) 0.66 (0.21-2.07) 1.24 (0.39-3.97) 
 Outpatients     
  Crude 1.0 1.13 (0.80-1.59) 1.91 (1.08-3.37) 3.48 (1.73-6.97) 
  Model1 1.0 1.01 (0.72-1.42) 1.35 (0.77-2.39) 2.03 (1.10-4.07) 
  Model2 1.0 0.95 (0.68-1.35) 1.26 (0.71-2.24) 1.85 (0.91-3.76) 
COPD     
 Inpatients     
  Crude 1.0 1.12 (0.85-1.48) 2.28 (2.78-8.76) 1.15 (0.43-3.07) 
  Model1 1.0 0.93 (0.70-1.22) 1.51 (0.99-2.30) 0.62 (0.23-1.65) 
  Model2 1.0 1.00 (0.76-1.33) 1.94 (1.27-2.97) 0.83 (0.31-2.23) 
 Outpatients     
  Crude 1.0 1.09 (0.99-1.19) 1.43 (1.20-1.70) 1.38 (1.03-1.85) 
  Model1 1.0 1.03 (0.94-1.13) 1.19 (1.00-1.41) 1.04 (0.77-1.39) 
  Model2 1.0 1.06 (0.97-1.17) 1.27 (1.07-1.52) 1.15 (0.85-1.55) 
Pulmonary disease     
 Inpatients     
  Crude 1.0 2.11 (1.40-3.18) 4.93 (2.78-8.76) 6.75 (3.01-15.12) 
  Model1 1.0 1.80 (1.19-2.72) 3.48 (1.96-6.19) 4.05 (1.81-9.08) 
  Model2 1.0 1.60 (1.06-2.44) 2.77 (1.53-5.03) 2.98 (1.27-7.02) 
 Outpatients     
  Crude 1.0 1.00 (0.58-1.74) 2.21 (0.99-4.94) 2.01 (0.50-8.04) 
  Model1 1.0 0.87 (0.50-1.50) 1.63 (0.73-3.66) 1.30 (0.32-5.23) 
  Model2 1.0 0.8 (0.50-1.53) 1.63 (0.71-3.71) 1.29 (0.31-5.36) 
Liver disease     
 Inpatients     
  Crude 1.0 1.61 (1.43-1.82) 1.80 (1.41-2.28) 1.96 (1.33-2.88) 
  Model1 1.0 1.52 (1.35-1.71) 1.60 (1.26-2.04) 1.68 (1.14-2.47) 
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  Model2 1.0 1.48 (1.32-1.67) 1.53 (1.20-1.94) 1.58 (1.06-2.35) 
 Outpatients     
  Crude 1.0 1.29 (1.22-1.36) 1.23 (1.10-1.38) 1.09 (0.89-1.33) 
  Model1 1.0 1.24 (1.18-1.31) 1.14 (1.02-1.29) 0.99 (0.80-1.21) 
  Model2 1.0 1.15 (1.09-1.22) 1.01 (0.90-1.13) 0.86 (0.70-1.06) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, current 
smoker, systolic blood pressure, anti-hypertensive, body mass index and dipstick proteinuria 
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Figure A1. Adjusted hazard ratios (95%CI) for indicators of incident non-CVD/cancer for 
eGFR<60 ml/min/1.73m2 (vs. ≥ 60) 
85 
 
 
 
HOSPITALIZATION
OUTPATIENT VISITS
Infectious disease
Viral hepatitis
Pneumonia
Diabetes
Renal failure
Parkinson
COPD
Pulmonary disease
Liver disease
Infectious disease
Viral hepatitis
Pneumonia
Diabetes
Renal failure
Parkinson
COPD
Pulmonary disease
Liver disease
Decreased   Increased
.1 .5 1 2 4 8 16
Hazard ratio 95% CI
 
Figure A2. Adjusted hazard ratios (95%CI) for indicators of incident non-CVD/cancer for 
positive proteinuria (vs. none/trace) 
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Table A7. Hazard ratios (95%CI) for cause-specific mortality by 1 year change in eGFR 
 Quartile of 1 year change in  eGFR 
 Q1 
(-58.83 to -10.61) 
Q2 
(-10.62 to -0.70) 
Q3 
(-0.71 to 10.31) 
Q4 
(10.32 to 95.34) 
 N=14,468 N=13,307 N=13,445 N=15,212 
Cancer mortality     
 Case 81 82 85 70 
 Crude 0.88 (0.65-1.19) 0.96 (0.71-1.30) 1.0 0.76 (0.55-1.04) 
 Model 1 0.97 (0.72-1.32) 1.00 (0.74-1.35) 1.0 0.80 (0.58-1.10) 
 Model 2  0.97 (0.71-1.32) 0.98 (0.72-1.32) 1.0 0.80 (0.58-1.10) 
CVD mortality     
 Case 36 33 24 23 
 Crude 1.38 (0.82-2.32) 1.37 (0.81-2.31) 1.0 0.89 (0.50-1.57) 
 Model 1 1.61 (0.95-2.70) 1.42 (0.84-2.41) 1.0 0.98 (0.55-1.74) 
 Model 2  1.58 (0.94-2.66) 1.37 (0.81-2.33) 1.0 0.96 (0.54-1.70) 
Non-CVD/cancer mortality     
 Case 51 60 72 39 
 Crude 0.65 (0.45-0.93) 0.83 (0.59-1.17) 1.0 0.50 (0.34-0.74) 
 Model 1 0.74 (0.51-1.06) 0.86 (0.61-1.21) 1.0 0.54 (0.37-0.80) 
 Model 2 0.74 (0.51-1.05) 0.83 (0.59-1.18) 1.0 0.54 (0.36-0.79) 
All-cause mortality     
 Case 168 175 181 132 
 Crude 0.86 (0.69-1.05) 0.96 (0.78-1.18) 1.0 0.67 (0.54-0.84) 
 Model 1 0.96 (0.78-1.19) 1.00 (0.81-1.23) 1.0 0.72 (0.58-0.91) 
 Model 2  0.96 (0.78-1.18) 0.97 (0.79-1.20) 1.0 0.72 (0.57-0.90) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, current smoker, systolic blood pressure, anti-hypertensive, 
body mass index and dipstick proteinuria 
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Table A8. Hazard ratios (95%CI) for cause-specific mortality by 2 year change in 
eGFR 
 2 years change 
in eGFR 
  
 Stable Uncertain drop Certain drop 
 N=19,009 N=30,630 N=1,094 
Cancer mortality    
 Case 144 198 12 
 Crude 1.0 0.81 (0.66-1.01) 1.15 (0.64-2.07) 
 Model 1 1.0 0.93 (0.75-1.16) 1.21 (0.67-2.19) 
 Model 2  1.0 0.95 (0.76-1.18) 1.30 (0.72-2.35) 
CVD mortality    
 Case 42 65 0 
 Crude 1.0 0.96 (0.65-1.42) 0.00 (0.00-0.00) 
 Model 1 1.0 1.10 (0.75-1.63) 0.00 (0.00-0.00) 
 Model 2  1.0 1.16 (0.78-1.71) 0.00 (0.00-0.00) 
Non-CVD/cancer 
mortality 
   
 Case 75 122 9 
 Crude 1.0 0.97 (0.73-1.39) 1.70 (0.85-3.41) 
 Model 1 1.0 1.10 (0.82-1.47) 1.82 (0.91-3.64) 
 Model 2 1.0 1.13 (0.84-1.51) 1.73 (0.85-3.49) 
All-cause mortality    
 Case 261 385 21 
 Crude 1.0 0.88 (0.75-1.03) 1.13 (0.72-1.76) 
 Model 1 1.0 1.01 (0.86-1.18) 1.20 (0.77-1.87) 
 Model 2  1.0 1.03 (0.88-1.21) 1.22 (0.78-1.92) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, 
current smoker, systolic blood pressure, anti-hypertensive, body mass index and dipstick 
proteinuria 
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Table A9. Hazard ratios (95%CI) for cause-specific mortality by 3 year change in eGFR 
 3 years change 
in eGFR 
  
 Stable Uncertain drop Certain drop 
 N=20,329 N=13,147 N=407 
Cancer mortality    
 Case 203 99 6 
 Crude 1.0 0.97 (0.69-1.38) 0.98 (0.48-2.03) 
 Model 1 1.0 0.98 (0.69-1.38) 1.00 (0.49-2.06) 
 Model 2  1.0 0.98 (0.69-1.39) 1.06 (0.51-2.20) 
CVD mortality    
 Case 52 34 2 
 Crude 1.0 0.84 (0.45-1.55) 1.39 (0.45-4.24) 
 Model 1 1.0 0.83 (0.45-1.54) 1.35 (0.44-4.09) 
 Model 2  1.0 0.83 (0.44-1.54) 1.25(0.40-3.86) 
Non-CVD/cancer 
mortality 
   
 Case 106 65 2 
 Crude 1.0 1.01 (0.60-1.70) 1.18 (0.44-3.19) 
 Model 1 1.0 1.01 (0.60-1.71) 1.17 (0.44-3.16) 
 Model 2 1.0 1.02 (0.61-1.72) 1.23 (0.45-3.36) 
All-cause mortality    
 Case 361 198 10 
 Crude 1.0 0.96 (0.74-1.24) 1.11 (0.66-1.85) 
 Model 1 1.0 0.96 (0.74-1.24) 1.11 (0.66-1.86) 
 Model 2  1.0 0.97 (0.74-1.25) 1.15 (0.69-1.94) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, 
current smoker, systolic blood pressure, anti-hypertensive, body mass index and dipstick 
proteinuria 
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Table A10. Hazard ratios (95%CI) for cause-specific mortality by 4 year change in eGFR 
 4 years change 
in eGFR 
  
 Stable Uncertain drop Certain drop 
 N=13,533 N=7,837 N=491 
Cancer mortality    
 Case 167 82 5 
 Crude 1.0 1.21 (0.82-1.79) 0.84 (0.40-1.78) 
 Model 1 1.0 1.15 (0.78-1.70) 0.92 (0.44-1.94) 
 Model 2  1.0 1.16 (0.78-1.71) 0.96 (0.46-2.03) 
CVD mortality    
 Case 49 26 0 
 Crude 1.0 0.67 (0.29-1.54) 1.29 (0.35-4.79) 
 Model 1 1.0 0.65 (0.29-1.50) 1.28 (0.34-4.73) 
 Model 2  1.0 0.69 (0.30-1.59) 1.37 (0.36-5.17) 
Non-CVD/cancer 
mortality 
   
 Case 82 56 3 
 Crude 1.0 0.88 (0.49-1.60) 1.08 (0.41-2.86) 
 Model 1 1.0 0.84 (0.46-1.53) 1.19 (0.45-3.13) 
 Model 2 1.0 0.83 (0.45-1.52) 1.08 (0.41-2.84) 
All-cause mortality    
 Case 298 164 8 
 Crude 1.0 1.04 (0.77-1.40) 0.97 (0.56-1.66) 
 Model 1 1.0 0.99 (0.73-1.34) 1.05 (0.61-1.79) 
 Model 2  1.0 1.00 (0.74-1.35) 1.03 (0.60-1.76) 
Model 1: adjusted for age and gender 
Model 2: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, 
current smoker, systolic blood pressure, anti-hypertensive, body mass index and dipstick 
proteinuria 
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Table A11. STATA command for analysis 
Imputation mi set wide 
mi register regular age female hx_cvd hx_can antihtn egfr dpr 
event_cvd1 event_can event_othe1 fu_death logflup 
mi register imputed cursmk sbp chol drink diabetes 
mi describe 
mi impute chained (regress) sbp chol (logit) drink cursmk diabetes=age 
female hx_cvd hx_can bmi antihtn event_cvd1 event_can event_othe1 
fu_death egfr dpr logflup, add(20) rseed(1) force 
Cox regression using 
multiple imputation 
capture program drop miPH_45 
program miPH_45 
    syntax  [if] 
     global full "age female chol diabetes hx_cvd hx_can cursmk sbp 
antihtn bmi" 
    foreach v in cvd1 can1 othe1 death { 
      mi stset fu_death, failure(event_`v'==1) 
         mi estimate, dots: stcox ib2.egfr3 i.dpr1 $full `if', nolog 
   }  
end 
Competing risks model capture program drop PH_com1 
program PH_com1 
    syntax  [if] 
    foreach v in can1 cvd1 othe1 { 
      mi stset fu_death, failure(event_`v'==1) 
   replace oth_death=0 if event_`v'==1 
         stcrreg ib2.egfr3 `if', nolog compete(oth_death==1) 
   stcrreg i.dpr1 `if', nolog compete(oth_death==1) 
   replace oth_death=event_death 
   }  
end 
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Spline with multiple 
imputation 
mkspline segfr1 30 segfr2 45 segfr3 60 segfr4 75 segfr5 90 segfr6 105 
segfr7=egfr 
 
mi stset fu_death, failure(event_death==1) id(id) 
mi estimate, vartable saving(miestfile, replace): stcox egfr? age female 
chol diabetes hx_cvd hx_can cursmk sbp antihtn bmi,nolog 
foreach v in age female chol diabetes hx_cvd hx_can cursmk sbp antihtn 
bmi { 
   replace `v'=0 
   } 
mi predict hr using miestfile 
mi predict stderr using miestfile, stdp 
 
gen hr1=exp(hr) 
gen lci=exp(hr-1.96*stderr) 
gen uci=exp(hr+1.96*stderr) 
 
twoway /// 
rarea lci uci egfr, color(ltblue) graphregion(fcolor(white)) /// 
    title("all-cause mortality") subtitle("Reference at eGFR=95") 
ytitle("HR") /// 
 xtitle("eGFR, ml/min/1.73{superscript:2}") xlabel(15 30 45 60 
75 90 105 120) /// 
    ylabel(0.5 1 2 4 8 ) yscale(log) xscale() yline(1, lcolor(gray)) || /// 
line hr1 egfr, clw(0.3) lcolor(black)|| /// 
rcap lci uci egfr, lcolor("230 170 170") lwidth(0.3) 
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ABSTRACT IN KOREAN 
 
만성신장질환 요인이 특정원인질환 사망 및 발생에 미치는 영향 
 
연세대학교 대학원 보건학과 
목 예 진 
 
만성신장질환은 동서양 지역 모두 10-15%의 유병률을 차지하고 있는 전 
세계적으로 증가하고 있는 질환 중 하나이며, 보건학적으로 문제가 대두되고 
있다. 이전의 많은 연구들은 사구체 여과율의 저하와 단백뇨에 따른 사망, 
특히 모든 원인에 의한 사망과 심장병으로 인한 사망과의 관련성을 
보고하였다. 하지만 신장질환과 암을 비롯한 그 외의 원인으로 인한 사망에 
대한 연구는 미비한 실정이다. 따라서 본 연구에서는 신장질환과 특정원인에 
의한 사망과의 관련성을 보고 신장질환이 사망을 예측함에 있어서 얼마나 
기여하는지 보고자 하였다. 
본 연구는 1994 년부터 2004 년까지 건강검진센터에서 검진을 받은 
367,932명(20~93세)의 대사증후군 사망연구(Metabolic Syndrome Mortality Study, 
MSMS)와 1996 년부터 2004 년까지 검진을 받은 233,219 명(30~74 세)의 한국인 
심장병 연구(Korean Heart Study, KHS)의 자료를 이용하였다. 사구체 
여과율(estimated glomerular filtration rate, eGFR)은 크레아티닌 수치를 이용한 
CKD-EPI 공식을 사용하였으며, dipstick 단백뇨(proteinuria)는 negative/trace, 1+, 
2+, 3+이상 군으로 나누었다. eGFR 과 proteinuria 와 특정원인 사망과의 
관련성을 보기 위해 Cox proportional hazard model을 이용하였다. 
 낮은 eGFR(<60ml/min/1.73m2 vs. ≥60ml/min/1.73m2)수치와 심장병[hazard ratio 
(HR)1.49(95%CI, 1.24-1.78)], 비심장병/암[1.78(1.54-2.05)]으로 인한 사망위험과 
통계적으로 유의한 관련성을 나타내었다. 암으로 인한 사망의 경우 eGFR 이 
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45-59 ml/min/1.73m2 인 군에서 가장 낮은 위험을 보였고, 이 군을 기준으로 
하였을 때 eGFR 이 45 ml/min/1.73m2 미만인 군에서 암으로 인한 사망의 
위험이 높게 나타났다 [1.62(1.10-2.39)]. 단백뇨(dipstick≥1+ vs. negative/trace)는 
심장병[1.93(1.66-2.25)], 암[1.49(1.32-1.68)], 비심장병/암[2.19(1.96-2.45)]으로 
인한 사망위험 모두 통계적으로 유의한 관련성을 보였다. 좀 더 세부적인 
사망원인을 보았을 때, 낮은 eGFR 수치는 허혈성심장병, 구인두암, 감염병, 
당뇨병과 신부전으로 인한 사망위험과 관련이 있었고, 단백뇨는 허혈성심장병, 
뇌혈관질환, 위암, 간암, 췌장암, 폐암, 골수종, 감염병, 당뇨병, 간질환과 
신부전으로 인한 사망위험과 관련이 있었다. 위의 결과를 질병발생 데이터에 
적용하여서 살펴보았을 때 비슷한 결과를 나타내었다. 또한, eGFR수치의 1년 
이내 급속한 감소는 심장병으로 인한 사망과 관련이 있었지만 다른 질환으로 
인한 사망과 관련은 없었다. 
낮은 eGFR 수치는 심장병과 비 심장병/암으로 인한 사망위험과 관련성이 
있는 반면에 단백뇨는 심장병, 암, 비 심장병/암으로 인한 사망위험과 
관련성을 나타내었다. 이러한 연구결과는 신장질환환자에게 다 학문적 예방과 
관리전략의 필요성을 제시한다. 
 
 
 
 
 
 
 
핵심되는 말: 사구체여과율, 단백뇨, 사망, 질환발생 
 
